Tag Archive for: Caboolture urologist

Robotic-Assisted Radical Prostatectomy: When Is a Non-Nerve-Sparing Procedure Necessary?

/0 Comments/in , /by

Removing the prostate while putting cancer control first

Robotic-assisted radical prostatectomy is a well-established surgical treatment for localised and selected locally advanced prostate cancer. During the operation, the prostate gland and seminal vesicles are removed, and the bladder is reconnected to the urethra. In selected patients, pelvic lymph nodes may also be removed.

One of the important decisions made before and during prostate cancer surgery is whether the nerves responsible for erections can safely be preserved.

This is known as nerve-sparing prostatectomy.

Unfortunately, nerve preservation is not always appropriate. When prostate cancer is close to, involves, or is suspected of extending beyond the outer edge of the prostate near these nerves, attempting to preserve them may compromise the completeness of cancer removal.

In this situation, a partial or complete non-nerve-sparing robotic prostatectomy may be recommended.

The guiding principle is simple:

Preserve the nerves when it is oncologically safe to do so, but do not preserve them at the expense of adequately treating the prostate cancer.

What are the nerves that are being “spared”?

Running immediately alongside the prostate are delicate bundles of nerves and blood vessels known collectively as the neurovascular bundles.

These structures contain nerves that play an important role in producing erections.

They sit extremely close to the outer surface, or capsule, of the prostate. This anatomical relationship creates a challenge during prostate cancer surgery.

If the cancer is safely contained within the prostate and sufficiently distant from the neurovascular bundle, the surgeon may be able to carefully dissect the prostate away while preserving the nerves.

This is a nerve-sparing radical prostatectomy.

If cancer is suspected to extend towards or through the prostate capsule in this area, the surgeon may need to remove some or all of the neurovascular tissue together with the prostate.

This is a non-nerve-sparing prostatectomy.

Why would a surgeon deliberately remove the erectile nerves?

It may initially seem counterintuitive to remove structures that are so important for sexual function.

The reason is cancer control.

The primary purpose of radical prostatectomy is to completely remove the prostate cancer.

If a tumour is growing very close to the edge of the prostate, particularly next to a neurovascular bundle, dissecting too close to the prostate in an attempt to preserve the nerves could potentially leave cancer cells behind.

This is called a positive surgical margin.

In appropriately selected patients, taking a wider margin around the prostate may therefore provide a safer cancer operation.

The decision represents a balance between:

Cancer control

and

preservation of erectile function.

When these two goals conflict, cancer control generally takes priority.

When may a non-nerve-sparing prostatectomy be recommended?

Non-nerve-sparing surgery may be considered when there is a significant risk that prostate cancer has extended towards or into the tissues surrounding the prostate.

Examples include:

Locally advanced prostate cancer

A tumour suspected of extending through the prostate capsule, particularly clinical T3 disease, may require a wider surgical excision.

Cancer close to the neurovascular bundle on MRI

Modern multiparametric prostate MRI can provide valuable information about the location of the tumour and its relationship to the prostate capsule and neurovascular bundles.

Features suggesting extraprostatic extension may influence the decision not to preserve the nerve bundle on that side.

High-grade prostate cancer

Higher-grade cancers, including cancers with an unfavourable Gleason score or ISUP Grade Group, may have a greater likelihood of extending outside the prostate.

The biopsy result alone does not automatically determine whether the nerves can be preserved, but it forms part of the overall assessment.

Extensive cancer on prostate biopsy

Large-volume disease, particularly when concentrated along the outer portion of the prostate near a neurovascular bundle, may make nerve preservation less appropriate.

Very high PSA or other high-risk features

PSA level, PSA density, biopsy findings, MRI appearance and clinical examination are considered together when estimating the likelihood of disease extending beyond the prostate.

Cancer involving one particular side of the prostate

Importantly, nerve sparing does not necessarily have to be “all or nothing.”

If the cancer is predominantly on one side, it may sometimes be possible to preserve the neurovascular bundle on the opposite side.

This is known as unilateral nerve sparing.

Nerve sparing is not simply YES or NO

Modern robotic prostate surgery is more nuanced than dividing operations into completely nerve-sparing and completely non-nerve-sparing procedures.

Depending on the location and extent of the cancer, surgery may involve:

  • Bilateral nerve sparing
  • Unilateral nerve sparing
  • Partial nerve sparing
  • Wider excision on one side and nerve preservation on the other
  • Complete bilateral non-nerve-sparing surgery

The surgical plan can therefore be tailored to the individual patient and, importantly, to the cancer on each side of the prostate.

How does nerve-sparing surgery differ from non-nerve-sparing surgery?

During nerve-sparing surgery, the surgeon carefully separates the neurovascular bundle from the surface of the prostate while attempting to minimise traction, heat and other potential injury to these delicate nerves.

During non-nerve-sparing surgery, the dissection is deliberately performed further away from the prostate.

The neurovascular tissue is removed together with the prostate where necessary to obtain a wider cancer margin.

The robotic platform provides magnified three-dimensional vision and highly controlled instrument movement. This allows the surgeon to identify tissue planes with considerable precision.

However, robotic technology cannot make an unsafe nerve-sparing operation safe.

The biology and location of the cancer ultimately determine how close to the prostate the surgeon can safely operate.

What happens to erections after non-nerve-sparing prostatectomy?

This is one of the most important issues to discuss before surgery.

The nerves surrounding the prostate are responsible for signalling increased blood flow into the penis to produce a natural erection.

If both neurovascular bundles are completely removed, the likelihood of recovering spontaneous erections adequate for sexual intercourse is very low.

This is different from nerve-sparing surgery, where the nerves remain anatomically intact but may temporarily function poorly following surgery.

After nerve-sparing prostatectomy, erectile recovery can occur gradually over many months and sometimes over 18–24 months or longer.

After complete bilateral non-nerve-sparing surgery, however, the nerves themselves have been removed rather than temporarily stunned.

The expectations for recovery are therefore very different.

Does non-nerve-sparing surgery affect sensation or orgasm?

This is an important distinction.

The nerves responsible for penile sensation are different from the neurovascular nerves primarily responsible for erections.

Many men can therefore continue to experience penile sensation and sexual pleasure following radical prostatectomy.

Orgasm may also remain possible.

However, radical prostatectomy removes the prostate and seminal vesicles and disconnects the reproductive pathway. Consequently, there is no ejaculation of semen after surgery.

This is sometimes described as a dry orgasm.

The sensation of orgasm can also feel different after prostate surgery.

Does non-nerve-sparing prostatectomy cause infertility?

Yes.

Radical prostatectomy results in permanent infertility because the prostate and seminal vesicles are removed and sperm can no longer enter the ejaculate.

Men who may wish to father children in the future should discuss sperm banking before surgery.

This applies whether the operation is nerve sparing or non-nerve sparing.

Is a non-nerve-sparing procedure reversible?

No.

Once a neurovascular bundle has been surgically removed, it cannot simply be reattached at a later date.

This is an important difference between temporary nerve dysfunction and actual nerve removal.

After nerve-sparing surgery, the nerves may be anatomically preserved but temporarily injured or “stunned”. Recovery may therefore occur with time.

After complete non-nerve-sparing surgery, the erectile nerves have been physically removed as part of the cancer operation.

The procedure itself is therefore not reversible.

However, this does not mean that erections or sexual activity are impossible.

There are several effective treatments available for erectile dysfunction following prostatectomy.

Can erections still be achieved after non-nerve-sparing surgery?

Rarely yes, but they will usually require assistance.

Treatment options include:

PDE5 inhibitor tablets

Medications such as sildenafil or tadalafil are commonly used after prostate surgery.

They rely substantially on functioning nerve pathways and are therefore generally more effective following nerve-sparing surgery.

Their effectiveness following complete bilateral non-nerve-sparing surgery is considerably more limited.

Vacuum erection device

A vacuum erection device creates negative pressure around the penis, drawing blood into the erectile tissues.

A constriction ring can then be placed around the base of the penis to maintain the erection.

Because this technique does not depend on intact erectile nerves, it can be useful after non-nerve-sparing surgery.

Penile injection therapy

Medication can be injected directly into the erectile tissue of the penis.

These medications act directly on penile blood vessels and therefore do not require normal prostate-associated nerve signalling.

For this reason, penile injections can be highly effective even after bilateral non-nerve-sparing prostatectomy.

Penile prosthesis

For men with persistent erectile dysfunction who wish to restore reliable erections, a penile prosthesis can provide an effective long-term solution.

An inflatable penile prosthesis allows an erection to be mechanically produced when desired.

For appropriately selected men, satisfaction rates following penile prosthesis surgery are generally high.

What about penile rehabilitation?

Penile rehabilitation may be discussed following radical prostatectomy.

The objectives can include maintaining penile tissue health, encouraging regular oxygenation of the erectile tissues, minimising shortening and fibrosis, and assisting the return to sexual activity.

A rehabilitation program may involve:

  • PDE5 inhibitor medication where appropriate
  • Vacuum erection therapy
  • Penile injection therapy
  • Regular sexual stimulation
  • Early assessment and management of erectile dysfunction

The appropriate program depends heavily on whether surgery was bilateral nerve sparing, unilateral nerve sparing or completely non-nerve sparing.

It is therefore important that expectations are realistic.

After complete bilateral nerve removal, rehabilitation cannot make the removed nerves grow back. Instead, treatment focuses on maintaining penile health and providing alternative ways of achieving an erection.

Can the surgeon decide during the operation whether to spare the nerves?

Sometimes.

The intended degree of nerve sparing is usually planned before surgery using information from:

  • Prostate MRI
  • Prostate biopsy
  • PSA
  • Clinical examination
  • Location and volume of cancer
  • Gleason score and ISUP Grade Group
  • Estimated risk of extraprostatic extension
  • The patient’s existing erectile function
  • The patient’s priorities regarding cancer control and sexual function

However, the final surgical approach may occasionally need to be modified according to findings encountered during the operation.

The most important objective remains adequate removal of the cancer.

Does non-nerve-sparing surgery improve cancer cure rates?

Not every patient benefits from wider surgery.

For men with cancer safely confined within the prostate, unnecessary removal of the neurovascular bundles may produce significant functional consequences without providing additional cancer benefit.

Conversely, when cancer is suspected of extending close to or beyond the prostate capsule adjacent to a neurovascular bundle, wider excision may reduce the risk of leaving tumour at the surgical margin.

This is why the decision must be individualised.

The best operation is not automatically the operation that preserves the most nerves. It is the operation that provides appropriate cancer clearance while preserving as much normal function as can safely be preserved.

What about urinary continence?

Nerve sparing primarily relates to erectile function, rather than the urinary sphincter responsible for continence.

Urinary control after radical prostatectomy depends on several factors including:

  • Age
  • Pre-operative urinary function
  • Pelvic floor strength
  • Urethral length
  • Bladder function
  • Surgical anatomy and technique
  • Previous prostate treatments
  • Individual healing

Pelvic floor rehabilitation before and after surgery can be an important part of recovery.

Non-nerve-sparing surgery does not automatically mean that a patient will remain incontinent.

Questions worth asking before surgery

If a non-nerve-sparing robotic prostatectomy has been recommended, useful questions to discuss with your urologist include:

Why is nerve preservation considered unsafe in my particular cancer?

Is the concern on one side or both sides of the prostate?

Could unilateral or partial nerve sparing be considered?

What does my MRI show about the relationship between the cancer and neurovascular bundles?

What is my estimated chance of erectile recovery with the proposed operation?

What erectile rehabilitation options will be available after surgery?

Should I consider sperm banking before treatment?

These conversations are particularly important because the decision to remove a neurovascular bundle is generally irreversible.

The important message

A non-nerve-sparing robotic-assisted radical prostatectomy is not an inferior version of nerve-sparing surgery.

In the right patient, it is a deliberate cancer-control strategy.

When prostate cancer is close to or suspected of involving the tissues surrounding the prostate, preserving the erectile nerves too aggressively may risk leaving cancer behind.

Modern robotic surgery allows the operation to be tailored to the individual patient. Some men can undergo bilateral nerve preservation, others may benefit from preservation on only one side, while patients with more extensive disease may require a wider non-nerve-sparing excision.

The consequences for erectile function are important and should be understood before surgery.

Once the neurovascular nerves have been removed, the procedure cannot be reversed.

However, loss of spontaneous erections does not mean the end of sexual intimacy. Vacuum devices, penile injection therapy and penile prostheses can provide effective options when natural erections are no longer possible.

Ultimately, the aim is to achieve the best possible balance between two important goals:

Effective treatment of the prostate cancer and preservation of quality of life.

A note for patients

Every prostate cancer is different. MRI findings, biopsy results, PSA, cancer grade, age, general health, pre-existing erectile function and personal priorities all influence the appropriate surgical approach.

A detailed discussion with your urologist before robotic prostatectomy is essential so that you understand whether nerve sparing is appropriate, what degree of nerve preservation may be possible and what this means for cancer control, continence and sexual function.

This information is intended for general patient education and does not replace individual medical advice. Treatment recommendations should be based on your individual prostate cancer characteristics, imaging, pathology, general health and discussion with your treating urologist.

Understanding Overactive Bladder: Symptoms, Assessment and Treatment Options

/2 Comments/in , , /by

Overactive bladder can make everyday life feel organised around the nearest toilet. Shopping, travelling, exercise, sleep and social activities may all be affected by sudden urgency, frequent urination or leakage.

It is common, but it is not simply an inevitable part of ageing. Symptoms deserve assessment because several bladder, urinary and medical conditions can produce a similar pattern.

This article explains overactive bladder as a condition and outlines the broad approaches used to investigate and manage it. It does not recommend a particular medicine, device or brand.

What is overactive bladder?

Overactive bladder (OAB) is a symptom syndrome characterised by urinary urgency, a sudden, compelling need to pass urine that is difficult to defer. It is usually accompanied by increased frequency during the day and waking at night to urinate, with or without urgency urinary incontinence.

Possible symptoms include:

  • a sudden need to urinate that is difficult to postpone
  • passing urine more frequently than expected
  • waking repeatedly at night to urinate
  • leaking urine before reaching the toilet
  • restricting travel or activities because of toilet access
  • using pads because of unpredictable urgency

OAB is a clinical diagnosis. Some people demonstrate involuntary bladder contractions, known as detrusor overactivity, during urodynamic testing; others with typical symptoms do not.

What causes the symptoms?

The bladder normally stores urine at low pressure and empties when it is convenient. OAB symptoms arise when the sensation or control of bladder filling becomes abnormal. The cause is not always identifiable.

Factors that can cause or aggravate similar symptoms include:

  • urinary tract infection
  • excessive caffeine, alcohol or fluid intake
  • medicines such as diuretics
  • constipation
  • poorly controlled diabetes
  • bladder stones
  • incomplete bladder emptying
  • bladder outlet obstruction
  • pelvic floor dysfunction
  • genitourinary syndrome of menopause
  • neurological conditions
  • reduced mobility or difficulty reaching a toilet
  • sleep disorders or fluid redistribution causing nocturia

Visible blood in the urine, recurrent infection, pelvic pain, difficulty passing urine or rapidly changing symptoms require further assessment rather than an assumption that OAB is the cause.

Overactive bladder in men

Urgency and frequency in men may occur alone or together with bladder outlet obstruction from prostate enlargement, urethral narrowing or impaired bladder contraction.

An assessment may therefore include the urinary stream, prostate, urinary flow and the amount of urine remaining after voiding. Treating urgency without recognising significant obstruction or incomplete emptying may worsen retention in some patients.

Overactive bladder after menopause

After menopause, reduced oestrogen can contribute to vaginal dryness, irritation, recurrent urinary infection, urgency and discomfort. These changes are often grouped under the term genitourinary syndrome of menopause.

Identifying vaginal or urinary tract changes is important because management may differ from treatment for isolated OAB. Any hormonal treatment requires an individual discussion of suitability, expected benefit, uncertainty and risk.

How is OAB assessed?

Assessment begins with listening to the pattern and impact of the symptoms. Depending on the individual, it may include:

  • a medical, urinary and medication history
  • examination
  • urinalysis or urine culture
  • a bladder diary
  • review of fluid, caffeine and alcohol intake
  • assessment of bowel function
  • measurement of urinary flow
  • ultrasound measurement of post-void residual urine
  • kidney-function or glucose testing when clinically indicated
  • assessment for pelvic organ prolapse or prostate enlargement

A bladder diary records the timing and volume of drinks, urination, urgency and leakage. It can help distinguish OAB from excessive urine production, nocturnal polyuria or habitual frequent voiding.

Are urodynamic studies always required?

No. Many patients with uncomplicated symptoms can begin conservative treatment without urodynamics.

Urodynamic testing may be helpful when the diagnosis is uncertain, bladder emptying is poor, previous treatment has failed, neurological dysfunction is suspected, or an invasive treatment is being considered. The test should answer a specific clinical question rather than be performed routinely.

When might cystoscopy or imaging be needed?

Cystoscopy or urinary tract imaging is not automatically required for uncomplicated OAB. It may be considered when there is blood in the urine, recurrent infection, pain, suspected stones, previous pelvic surgery, obstruction or another concerning feature.

First steps in management

Conservative treatment is often the starting point and may be used alone or with other therapies.

Bladder training

Bladder training aims to increase the interval between toilet visits and reduce the habit of urinating “just in case.” A planned program may involve:

  • recording voiding patterns
  • gradually extending the interval between voids
  • using distraction, breathing or pelvic floor contractions when urgency occurs
  • avoiding rushing to the toilet where it is safe to pause

Progress is usually gradual. An unrealistic schedule can lead to frustration or increased leakage.

Pelvic floor rehabilitation

Pelvic floor exercises may help suppress urgency and improve continence. Correct technique matters; repeatedly contracting the wrong muscles or performing excessive exercises may be unhelpful. Assessment by a pelvic floor physiotherapist can be useful.

Fluids and bladder irritants

Reducing excessive caffeine or alcohol may improve symptoms. Large volumes of fluid over a short period can also provoke urgency.

Fluid should not be restricted excessively. Concentrated urine may irritate the bladder and inadequate intake can contribute to constipation, infection or dehydration. Advice should reflect medical conditions, climate and activity.

Constipation, weight and mobility

Treating constipation may reduce pressure on the bladder. Weight reduction can improve urinary symptoms for some people. Mobility aids, clear access to the toilet and suitable clothing can reduce functional leakage even when bladder symptoms persist.

Managing nocturia

Waking at night to urinate is not always caused by OAB. Other contributors include sleep apnoea, leg swelling, heart or kidney disease, evening fluid intake and medicines.

Management should be directed at the cause. Moving a diuretic to a different time, for example, should occur only on advice from the prescribing clinician.

Where do prescription medicines fit?

Prescription medicines may be discussed when conservative measures have not provided sufficient relief, when symptoms are particularly troublesome, or when a combined approach is appropriate.

Two broad medicine classes are commonly used:

  1. Antimuscarinic medicines, which reduce muscarinic stimulation of the bladder.
  2. Beta-3 adrenergic agonists, which promote bladder relaxation during filling.

These medicines are not suitable for everyone. The choice should follow an individual assessment of symptoms, bladder emptying, other medical conditions, current medicines and personal priorities.

Antimuscarinic medicines

This class may reduce urgency, frequency and urgency incontinence in some patients. Possible adverse effects include:

  • dry mouth
  • constipation
  • blurred vision or dry eyes
  • dizziness or drowsiness
  • difficulty emptying the bladder
  • urinary retention
  • confusion or cognitive effects, particularly in susceptible older people

Caution may be required in people with impaired bladder emptying, certain forms of glaucoma, severe constipation or gastrointestinal motility disorders, cognitive impairment, or a high total anticholinergic burden.

Anticholinergic burden and cognition

Many medicines used for conditions other than OAB also have anticholinergic effects. The combined burden may contribute to dry mouth, constipation, sedation, falls, confusion and loss of function.

Observational research has found associations between prolonged exposure to medicines with strong anticholinergic effects and cognitive decline or dementia. An association does not prove that a particular medicine caused dementia in an individual patient, but the overall medication burden deserves review—especially in older people or those with cognitive concerns.

Beta-3 adrenergic agonists

This class acts differently and generally produces fewer classic anticholinergic effects. Possible adverse effects can include:

  • increased blood pressure
  • headache
  • palpitations or faster heart rate
  • urinary tract infection
  • difficulty emptying the bladder
  • medicine interactions

Blood pressure, cardiovascular history, kidney or liver function, bladder emptying and interacting medicines may influence suitability. Current Australian Product Information should guide prescribing and monitoring.

Can medicine classes be combined?

Combination therapy may be considered after a partial response to a single medicine, but additional benefit must be weighed against increased adverse effects, interactions and cost.

In men with both storage symptoms and possible bladder outlet obstruction, treatment may also need to address the obstructive component. A urinary flow test and post-void residual measurement may help guide the decision.

How is a medicine trial reviewed?

A medicine trial should have a clear purpose and review point. Reassessment may consider:

  • urgency episodes
  • daytime and night-time frequency
  • leakage and pad use
  • bladder diary findings
  • quality of life
  • blood pressure where relevant
  • constipation, dry mouth, cognition or other adverse effects
  • urinary flow and residual urine in patients at risk of retention

If there is little benefit or unacceptable harm, the diagnosis and management plan should be reconsidered. Increasing or continuing treatment indefinitely is not automatically appropriate.

Patients should not start, stop or change a prescription medicine without advice from their prescriber.

What if conservative care and medicines are insufficient?

Persistent symptoms do not mean that no further options exist. Reassessment is important before an invasive treatment to confirm the likely cause and identify incomplete emptying, obstruction or another condition.

Depending on the patient, options may include:

Intravesical botulinum toxin treatment

A prescription medicine can be injected into the bladder wall through a cystoscope to reduce involuntary bladder contractions. Some patients experience reduced urgency and leakage, but benefit varies and is temporary.

Important risks include urinary tract infection, increased residual urine and inability to empty the bladder adequately. Some patients require temporary intermittent self-catheterisation. Treatment must be selected and administered by an appropriately qualified clinician.

Tibial nerve stimulation

Electrical stimulation near the ankle can influence the nerve pathways involved in bladder control. Treatment protocols vary, and repeated sessions may be required. Response is variable.

Sacral neuromodulation

Sacral neuromodulation uses an implanted system to stimulate nerves involved in bladder and pelvic-floor control. It may be considered for selected patients after assessment and usually involves a test phase. Potential disadvantages include an operation, device-related complications, later revision and ongoing follow-up.

These treatments differ in invasiveness, risks, durability, repeat-treatment requirements, availability and cost. None is the best choice for every patient.

When should medical advice be sought promptly?

Prompt assessment is appropriate for:

  • inability to pass urine
  • visible blood in the urine
  • fever, flank pain or systemic illness with urinary symptoms
  • recurrent urinary infections
  • new leg weakness, numbness or loss of bowel control
  • significant pelvic or bladder pain
  • rapidly worsening symptoms
  • new incontinence accompanied by neurological symptoms

Urgent or emergency care may be required when symptoms are severe.

Questions to discuss with a clinician

  • Are my symptoms most consistent with OAB, or could there be another cause?
  • Am I emptying my bladder adequately?
  • Which conservative measures are most relevant to me?
  • What are the reasonable treatment options, including no immediate treatment?
  • What benefit might I realistically expect?
  • Which adverse effects or interactions matter with my other conditions and medicines?
  • How and when will treatment be reviewed?
  • Would further testing change management?
  • What symptoms should prompt urgent assessment?

The bottom line

Overactive bladder is a symptom syndrome, not a single test result. Assessment should look for infection, excessive urine production, incomplete emptying, obstruction, menopause-related changes, neurological disease and other contributors.

Management usually begins with education, bladder training, pelvic floor rehabilitation and attention to fluids, caffeine, constipation and related medical problems. Prescription medicine may be one part of treatment after an individual assessment, but benefits vary and adverse effects matter.

When symptoms remain troublesome, further evaluation and carefully selected minimally invasive treatments may be considered. The aim is not simply to prescribe another tablet; it is to understand the cause, reduce symptoms safely and improve daily life.

This article provides general disease education and does not replace individual medical advice. It does not promote or recommend a particular prescription medicine, therapeutic product, device or brand. Treatment decisions should be made with an appropriately qualified health professional after assessment of the individual patient.

References and further reading

Publication note

This draft is structured as general disease education for an Australian public-facing website. It should not be accompanied by branded medicine or device imagery, product pricing, supply information, testimonials, inducements, superiority claims, or wording that encourages a reader to request a named therapeutic good. Review the page title, search metadata, images, links, social-media caption and nearby booking prompts together, because the overall context determines whether material may be regarded as advertising.

Upper Tract Urothelial Carcinoma

/0 Comments/in , , /by

Cancer of the Renal Pelvis and Ureter

Urothelial carcinoma is most commonly associated with the bladder, but the same specialised lining extends all the way from the bladder up the ureters and into the collecting system of each kidney.

When a urothelial cancer develops in the renal pelvis or ureter, it is called upper tract urothelial carcinoma (UTUC).

UTUC is considerably less common than bladder cancer. Importantly, its behaviour varies enormously. Some tumours are small, superficial and relatively slow growing, while others are aggressive cancers capable of invading the kidney, surrounding tissues, lymph nodes and distant organs.

The key to successful management is therefore not simply finding the tumour, but determining how aggressive it is and how likely it is to spread.

What Is the Upper Urinary Tract?

Urine produced by the kidney drains through:

Kidney → renal calyces → renal pelvis → ureter → bladder → urethra

The inner surface of the renal pelvis, ureter and bladder is covered by urothelium, previously called transitional epithelium.

Cancer arising from these cells is called urothelial carcinoma.

UTUC can therefore occur in:

  • the renal pelvis;
  • one or more renal calyces;
  • the upper, middle or lower ureter;
  • multiple areas of the same urinary tract; or
  • occasionally both upper urinary tracts.

Patients with UTUC may also develop urothelial tumours within the bladder, either at the same time or later.

What Causes Upper Tract Urothelial Cancer?

Cancer develops when genetic damage accumulates within urothelial cells, allowing them to grow and divide abnormally.

Frequently there is no single identifiable cause, but several important risk factors are recognised.

Smoking

Cigarette smoking is one of the most important preventable risk factors for urothelial carcinoma.

Carcinogenic chemicals absorbed through the lungs enter the bloodstream, are filtered by the kidneys and become concentrated in the urine. The urothelium may therefore be exposed to these substances for many years.

Stopping smoking remains important even after diagnosis because of its wider health benefits and potential relevance to future urothelial cancer risk.

Previous bladder cancer

Patients who have previously had urothelial carcinoma of the bladder have an increased risk of developing urothelial carcinoma elsewhere within the urinary tract.

Similarly, patients treated for UTUC remain at risk of subsequently developing bladder cancer.

Occupational chemical exposure

Long-term exposure to certain industrial chemicals, particularly some aromatic amines historically associated with dye, rubber, textile, leather and chemical industries, has been associated with urothelial cancer.

Lynch syndrome

A small but important proportion of UTUC occurs in people with Lynch syndrome, an inherited disorder caused by abnormalities in DNA mismatch-repair genes.

UTUC, particularly in a younger patient or someone with a strong family history of bowel, endometrial or other Lynch-associated cancers, may prompt consideration of genetic assessment.

Chronic inflammation

Long-standing urinary tract inflammation and some chronic infections may contribute to malignant change. Chronic stone disease has particularly been associated with squamous carcinoma of the renal pelvis, which is a different and much less common tumour type.

Previous analgesic exposure

Heavy historical exposure to certain analgesics, particularly phenacetin-containing preparations that are no longer routinely used in many countries, has been associated with upper tract urothelial malignancy.

What Are the Symptoms?

Blood in the urine

The most common warning sign is:

Haematuria: blood in the urine

This may be obvious, turning the urine pink, red or occasionally dark brown.

Importantly, haematuria may:

  • occur only once;
  • disappear for weeks or months;
  • be completely painless; or
  • only be detected microscopically on a urine test.

Visible blood in the urine should always be appropriately investigated, particularly in adults.

Do not assume that painless bleeding is simply due to infection, prostate enlargement or a blood-thinning medication without appropriate assessment.

Flank or loin pain

A tumour can obstruct drainage of urine from the kidney.

This may produce:

  • persistent flank discomfort;
  • loin pain;
  • renal colic;
  • hydronephrosis, where the kidney becomes dilated because urine cannot drain normally.

Blood clots passing down the ureter can occasionally produce severe colicky pain resembling a kidney stone.

Recurrent urinary symptoms

Some patients experience:

  • urinary frequency;
  • urgency;
  • burning when passing urine;
  • recurrent apparent urinary tract infections.

These symptoms are much more commonly caused by benign conditions, but persistent or unexplained symptoms may warrant further investigation.

General symptoms

More advanced disease can occasionally cause:

  • unexplained weight loss;
  • loss of appetite;
  • fatigue;
  • persistent pain;
  • anaemia.

Fortunately, many tumours are detected before these symptoms develop.

How Is UTUC Diagnosed?

Investigation usually involves several complementary tests.

1. Urine testing

Urine is assessed for:

  • microscopic blood;
  • infection;
  • renal abnormalities; and
  • sometimes malignant cells.

Urine cytology

Urine cytology examines shed urinary cells under a microscope.

It is particularly useful for detecting high-grade urothelial carcinoma, although a negative cytology result does not completely exclude cancer.

Selective urine samples may sometimes be collected directly from the affected upper urinary tract.

2. CT Urography

CT urography is one of the most important imaging investigations for suspected UTUC.

Contrast-enhanced CT imaging allows assessment of:

  • the kidneys;
  • renal collecting systems;
  • ureters;
  • bladder;
  • lymph nodes; and
  • surrounding organs.

A tumour may appear as a filling defect, thickening of the ureter or renal pelvis, or an infiltrating mass.

CT can also identify obstruction and hydronephrosis.

3. Cystoscopy

Because urothelial cancer can occur at more than one location, the bladder should generally also be examined.

A flexible cystoscope is passed through the urethra into the bladder to look for associated bladder tumours.

Ureteroscopy and Biopsy

Sometimes imaging alone cannot provide enough information about the tumour.

A ureteroscope is a very fine telescope passed through the urethra and bladder and then into the ureter and renal collecting system.

This allows the urologist to directly inspect the tumour.

During ureteroscopy it may be possible to:

  • identify the location of the tumour;
  • assess whether there is one tumour or several;
  • estimate its size;
  • obtain selective urine cytology;
  • take a biopsy; and
  • in selected low-risk tumours, treat the lesion with a laser.

Biopsy is particularly helpful in determining whether the tumour is low-grade or high-grade.

An important limitation is that ureteroscopic biopsy samples are small, so determining the exact depth of invasion before definitive surgery can sometimes be difficult.

Low-Risk Versus High-Risk Disease

Modern management increasingly divides UTUC according to its risk of invasion and progression.

Factors considered include:

  • tumour grade;
  • appearance on CT;
  • tumour size;
  • number of tumours;
  • presence of hydronephrosis;
  • urine cytology;
  • ureteroscopic appearance;
  • biopsy findings;
  • evidence of invasion; and
  • previous urothelial cancer.

This distinction is extremely important because treatment can range from relatively conservative endoscopic therapy to removal of the entire kidney and ureter.

Treatment of Low-Risk UTUC

Selected patients with low-risk disease may be suitable for kidney-sparing treatment.

The objective is to control the cancer while preserving as much functioning kidney tissue as possible.

Ureteroscopic Laser Treatment

A ureteroscope is passed to the tumour and the lesion is treated using laser energy.

Laser treatment can:

  • vaporise;
  • coagulate; or
  • fragment the tumour.

Modern flexible ureteroscopes allow access to much of the renal collecting system.

Advantages

Kidney-sparing treatment may:

  • preserve kidney function;
  • avoid major abdominal surgery;
  • reduce recovery time;
  • be particularly valuable in patients with impaired kidney function or a solitary kidney.

Disadvantages

The trade-off is the need for very careful surveillance.

UTUC has a tendency to recur, so patients may require repeated:

  • ureteroscopy;
  • urine cytology;
  • CT imaging; and
  • occasionally further laser treatments or biopsies.

Kidney preservation therefore does not mean that the tumour can simply be treated once and forgotten.

Segmental Ureterectomy

Some tumours confined to a relatively short section of ureter can be treated by removing only the affected portion.

This is known as segmental ureterectomy.

It is particularly useful for appropriately selected tumours of the distal ureter.

The affected segment is removed and the remaining ureter is either reconnected or reimplanted into the bladder.

This can preserve the kidney while providing a complete surgical specimen for pathological examination.

Treatment of High-Risk UTUC

For patients with high-risk localised disease, the standard definitive operation is generally:

Radical Nephroureterectomy

This involves removal of:

the kidney + entire ureter + a cuff of bladder surrounding the ureteric opening

Removing the complete ureter is important because leaving part of the affected ureter behind may allow cancer to recur within the remaining urothelium.

The procedure can often be performed using:

  • robotic surgery;
  • laparoscopic surgery; or
  • occasionally open surgery.

The choice depends upon tumour characteristics, anatomy, previous surgery and individual circumstances.

What About the Lymph Nodes?

For selected high-risk tumours, lymph nodes draining the affected area may also be removed.

A lymph-node dissection can provide important staging information and may be incorporated into the surgical management of appropriately selected high-risk disease.

Chemotherapy

Systemic chemotherapy plays an important role in selected patients with higher-risk UTUC.

Platinum-based chemotherapy, particularly cisplatin-containing treatment, has traditionally formed an important part of systemic treatment.

Chemotherapy may be given:

Before surgery: neoadjuvant chemotherapy

One potential advantage is that both kidneys are still present, and renal function may therefore be better able to tolerate cisplatin.

After surgery: adjuvant chemotherapy

Chemotherapy may be recommended after nephroureterectomy when the final pathology demonstrates sufficiently high-risk disease.

An important consideration is that removing a kidney can reduce renal function, potentially affecting the patient’s ability to receive certain chemotherapy drugs.

Treatment decisions are therefore ideally made by a multidisciplinary uro-oncology team.

Immunotherapy and Newer Treatments

The treatment of advanced urothelial carcinoma has changed considerably in recent years.

Depending upon the stage, previous treatment and molecular characteristics of the cancer, systemic therapy may include combinations of:

  • platinum-based chemotherapy;
  • immune checkpoint inhibitors;
  • antibody-drug conjugates; and
  • targeted treatments for selected molecular abnormalities such as FGFR alterations.

These treatments are particularly relevant to patients with locally advanced, recurrent or metastatic disease.

Treatment is increasingly individualised according to the biological characteristics of the tumour and the patient’s kidney function and overall health.

Treatment Placed Directly Into the Upper Urinary Tract

For carefully selected non-invasive disease, medication may sometimes be delivered directly into the renal pelvis and ureter.

Options can include topical chemotherapy or immunotherapy in selected circumstances.

A chemoablative gel formulation of mitomycin has also been developed for selected low-grade UTUC, allowing prolonged contact between chemotherapy and the tumour.

These treatments are specialised and are not suitable for every patient.

What Happens After Treatment?

Follow-up is particularly important because urothelial carcinoma has a characteristic ability to develop at another point along the urinary tract.

After treatment, surveillance may include:

  • cystoscopy;
  • urine cytology;
  • CT urography or other upper-tract imaging;
  • blood tests to assess kidney function;
  • ureteroscopy following kidney-sparing treatment.

The exact surveillance schedule depends upon whether the original tumour was low or high risk and what treatment was performed.

Can the Cancer Return in the Bladder?

Yes.

One of the distinctive features of UTUC is the significant risk of subsequently developing urothelial carcinoma within the bladder.

Published data have reported subsequent bladder tumours in a substantial proportion of patients following treatment of UTUC.

For this reason, regular cystoscopic surveillance remains important even when the original kidney or ureteric tumour has been completely removed.

What Is the Prognosis?

The outlook for UTUC depends predominantly upon:

  • tumour stage;
  • tumour grade;
  • lymph-node involvement;
  • metastatic spread;
  • tumour multifocality;
  • response to treatment; and
  • certain pathological and molecular characteristics.

The most important question is whether the cancer remains superficial or has invaded deeply through the wall of the renal pelvis or ureter.

Superficial, localised disease

The outlook can be excellent when a tumour is identified while still superficial and confined to the upper urinary tract. The National Cancer Institute reports that more than 90% of superficial cancers confined to the renal pelvis or ureter may be curable.

Invasive disease

Once a tumour has invaded deeply into the wall or surrounding tissues, the risk of lymph-node involvement and distant spread increases substantially.

High-grade and invasive tumours therefore usually require more aggressive treatment and closer surveillance.

Metastatic disease

When UTUC has spread to distant organs, treatment is generally systemic rather than surgical alone.

Although metastatic UTUC remains a serious disease, modern systemic treatments have expanded considerably and can provide meaningful cancer control for selected patients.

UTUC and Kidney Function

Preserving kidney function is an important part of treatment planning.

Removing one kidney is usually well tolerated when the opposite kidney is healthy, but kidney function can become particularly important in patients with:

  • pre-existing chronic kidney disease;
  • diabetes;
  • hypertension;
  • a solitary kidney;
  • bilateral upper-tract tumours; or
  • conditions likely to affect future kidney function.

The decision between kidney-sparing treatment and radical nephroureterectomy therefore involves balancing two priorities:

adequate cancer control and preservation of renal function.

Cancer safety remains the priority, but in appropriately selected low-risk disease these objectives can often coexist.

When Should You See a Urologist?

Seek medical assessment if you develop:

  • visible blood in the urine;
  • persistent microscopic haematuria;
  • unexplained flank or loin pain;
  • recurrent unexplained urinary symptoms;
  • abnormal findings on kidney imaging; or
  • haematuria with a previous history of urothelial cancer.

Blood in the urine should not automatically be attributed to prostate enlargement, infection, kidney stones or blood-thinning medication without appropriate investigation.

The Bottom Line

Upper tract urothelial carcinoma is an uncommon cancer arising from the lining of the renal pelvis or ureter.

Blood in the urine is its most important warning sign.

Investigation commonly involves CT urography, cystoscopy, urine cytology and, when required, ureteroscopy with biopsy.

Treatment is increasingly tailored to the biological risk of the tumour.

Small, low-grade tumours may sometimes be managed with kidney-sparing ureteroscopic laser treatment or segmental surgery, while high-risk invasive cancers generally require radical nephroureterectomy with removal of the bladder cuff, sometimes combined with lymph-node surgery and systemic treatment.

Long-term surveillance is essential because urothelial cancer can recur elsewhere within the urinary tract, particularly the bladder.

The reassuring part is that when UTUC is detected while still superficial and localised, the likelihood of successful treatment can be very high.

A Note for Patients

Every upper tract urothelial tumour is different. Treatment depends upon the tumour’s location, size, grade, stage, number of lesions, kidney function and your general health.

Management should therefore be individualised following discussion with your urologist and, for higher-risk disease, a multidisciplinary uro-oncology team.

This information is intended for general patient education and should not replace individual medical advice, examination or treatment recommendations from your treating specialist.

The current 2026 EAU guideline specifically incorporates updated risk stratification, kidney-sparing management, bladder-cuff and lymph-node considerations, systemic therapy, and follow-up recommendations.

Kidney Stones: Understanding the Different Types of Renal Calculi and Their Treatment

/0 Comments/in , /by

Kidney stones, medically known as renal calculi or nephrolithiasis, are solid crystalline deposits that develop within the kidneys. Although we tend to talk about “a kidney stone” as if all stones are the same, there are several distinctly different types.

Knowing the composition of a kidney stone matters. Different stones have different causes, appearances, recurrence risks and, importantly, different strategies for prevention and treatment.

Modern management therefore involves more than simply removing the stone. The aim is to answer three questions:

What is the stone? Why did it form? And how can we prevent the next one?

What Are Kidney Stones Made Of?

The major types of urinary stones are:

  1. Calcium oxalate stones
  2. Calcium phosphate stones
  3. Uric acid stones
  4. Struvite or infection stones
  5. Cystine stones
  6. Rare metabolic and medication-related stones

Stones are not always chemically pure. Many contain a mixture of different crystalline components.

The European Association of Urology recommends reliable stone analysis and a basic metabolic evaluation in stone-forming patients, with more detailed metabolic investigation particularly important in patients at high risk of recurrence.

1. Calcium Oxalate Stones

The most common kidney stone

Calcium oxalate stones are the most frequently encountered urinary calculi.

They may consist predominantly of:

  • Calcium oxalate monohydrate, known as whewellite
  • Calcium oxalate dihydrate, known as weddellite

Calcium oxalate monohydrate stones can be particularly hard and resistant to fragmentation with shockwave lithotripsy.

Why do calcium oxalate stones form?

Contributing factors may include:

  • Low urine volume or dehydration
  • Excess urinary calcium
  • Excess urinary oxalate
  • Low urinary citrate
  • High dietary sodium intake
  • Excessive animal protein intake
  • Certain bowel diseases or previous intestinal surgery
  • Genetic predisposition
  • Metabolic abnormalities

Importantly, calcium stones do not necessarily mean that a patient is eating too much calcium.

Severely restricting normal dietary calcium can actually be counterproductive because calcium within the intestine binds oxalate and reduces its absorption.

Management

Small asymptomatic stones may sometimes simply be monitored.

When treatment is required, options include:

  • Shockwave lithotripsy (SWL)
  • Flexible ureteroscopy and laser lithotripsy
  • Percutaneous nephrolithotomy (PCNL)
  • Observation in appropriately selected patients

Prevention depends on the underlying metabolic abnormality and may include increased fluid intake, dietary modification, reduction in excessive sodium intake, potassium citrate for selected patients, thiazide therapy for hypercalciuria and treatment of hyperoxaluria or hyperuricosuria when identified.

2. Calcium Phosphate Stones

Calcium phosphate stones are less common than calcium oxalate stones.

They may contain:

  • Hydroxyapatite
  • Carbonate apatite
  • Brushite

Why do they form?

Calcium phosphate crystallisation is favoured by relatively alkaline urine.

They may be associated with:

  • Hypercalciuria
  • Renal tubular acidosis
  • Hyperparathyroidism
  • Urinary tract abnormalities
  • Certain metabolic disorders

Brushite stones deserve particular attention. They can be extremely hard and may respond poorly to shockwave treatment.

Management therefore needs to consider not only stone size and location, but also stone density and previous stone composition.

3. Uric Acid Stones

Uric acid stones behave very differently from calcium stones.

They are strongly associated with persistently acidic urine and may occur in patients with:

  • Gout
  • Metabolic syndrome
  • Diabetes
  • Obesity
  • High purine intake
  • High animal-protein intake
  • Chronic dehydration
  • Excessive uric acid production or excretion

Uric acid stones account for approximately 10% of renal stones and all uric acid stone formers are considered at increased risk of recurrence.

Why are uric acid stones special?

Because unlike most kidney stones, uric acid stones can potentially be dissolved.

Treatment involves increasing urinary pH, usually using an alkalinising medication such as potassium citrate.

For active oral dissolution therapy, urinary pH needs to be carefully monitored. Current EAU guidance describes targeting approximately pH 7.0–7.2 during chemolysis, while avoiding excessive alkalinisation because this may encourage calcium phosphate crystallisation.

This creates one of the happier conversations in stone management:

“You have a kidney stone, but we may be able to make it disappear without an operation.”

Not every uric acid stone will dissolve successfully, and obstructed or infected kidneys require separate and sometimes urgent treatment.

4. Struvite Stones: The Infection Stones

Struvite stones contain magnesium ammonium phosphate and are closely associated with urinary infections caused by certain urease-producing bacteria.

These bacteria change the chemistry of the urine, producing an alkaline environment favourable for rapid stone formation.

Struvite stones can become very large and occasionally form a branching staghorn calculus, occupying much of the kidney’s collecting system.

Why are these stones important?

The stone and infection can maintain one another.

Leaving significant infected stone material behind may therefore contribute to:

  • Recurrent urinary infection
  • Rapid stone regrowth
  • Kidney damage
  • Sepsis

Management generally involves treating the infection and achieving as complete a stone clearance as reasonably possible. Large stones frequently require PCNL, sometimes performed in more than one stage.

Infection stone formers are regarded as being at high risk of recurrence.

5. Cystine Stones

Cystine stones are uncommon and are caused by cystinuria, an inherited disorder affecting the transport of certain amino acids through the kidneys.

Cystine is relatively insoluble in urine and can crystallise to form stones.

These patients may start developing stones at a young age and can experience repeated stone episodes throughout life.

Treatment and prevention

Prevention is particularly important and may involve:

  • Very high fluid intake
  • Reduced dietary sodium
  • Urinary alkalinisation
  • Potassium citrate
  • Specialist medication such as tiopronin in selected recurrent cases

Current EAU guidance recommends aiming for a urine volume greater than 3 litres per day in adults with cystinuria and maintaining urinary pH above approximately 7.5 to improve cystine solubility.

Cystine stones are also relatively hard, which can make shockwave treatment less successful. Ureteroscopy with laser treatment or PCNL may therefore be required depending on stone burden.

6. Rare Kidney Stones

Much less commonly, stones may consist of substances such as:

  • Xanthine
  • 2,8-dihydroxyadenine
  • Ammonium urate
  • Matrix material
  • Medication-related crystalline material

These stones can sometimes provide the first clue to an underlying metabolic, genetic or medication-related disorder.

Recurrent unusual stones therefore deserve specialist investigation rather than simply repeated stone removal.

How Do Kidney Stones Present?

Some kidney stones sit quietly within the kidney and are discovered incidentally during an ultrasound or CT scan.

Others announce their arrival with considerably less subtlety.

A stone entering and obstructing the ureter may cause renal colic, producing severe pain from the loin toward the abdomen or groin.

Other symptoms can include:

  • Blood in the urine
  • Nausea and vomiting
  • Urinary urgency or frequency
  • Burning during urination
  • Recurrent urinary infection
  • Fever or chills
  • Intermittent loin discomfort

Fever plus an obstructed kidney is an emergency

An infected obstructed urinary system can progress rapidly to urosepsis.

Urgent drainage with a ureteric stent or nephrostomy tube, together with appropriate antibiotics and supportive treatment, may be required. Definitive stone treatment is generally delayed until the infection has been controlled.

How Are Kidney Stones Investigated?

CT Scan

A non-contrast CT scan of the kidneys, ureters and bladder provides detailed information regarding:

  • Stone size
  • Number of stones
  • Exact location
  • Degree of obstruction
  • Kidney anatomy
  • Stone density measured in Hounsfield units

CT density may also provide clues about stone composition and the likelihood of successful shockwave fragmentation.

Ultrasound

Ultrasound avoids radiation and is particularly useful for:

  • Surveillance
  • Detecting hydronephrosis
  • Monitoring known renal stones
  • Selected younger patients
  • Pregnancy

However, very small stones and ureteric stones can sometimes be difficult to identify accurately.

Plain X-ray

A KUB X-ray may be useful for monitoring certain radiopaque stones.

Calcium-containing stones are usually radiopaque, whereas uric acid stones are typically radiolucent on plain X-ray.

Do All Kidney Stones Need Treatment?

No.

A small, non-obstructing and asymptomatic kidney stone may sometimes be monitored with periodic imaging.

Treatment becomes more appropriate when there is:

  • Stone growth
  • Recurrent pain
  • Haematuria
  • Urinary obstruction
  • Recurrent infection
  • Declining renal function
  • Significant stone burden
  • High risk of future complications
  • Occupational or travel considerations
  • Patient preference

These factors are reflected in contemporary EAU recommendations.

Treatment Options for Kidney Stones

1. Active Surveillance

Small asymptomatic renal stones can sometimes be observed.

Follow-up may include ultrasound, X-ray or CT depending on the type, size and visibility of the stone.

The advantage is obvious: no procedure unless one becomes necessary.

The disadvantage is equally obvious: stones have not signed a contract promising to remain where they are.

They may enlarge, migrate into the ureter, cause obstruction or become symptomatic.

2. Shockwave Lithotripsy

Extracorporeal shockwave lithotripsy (SWL) uses externally generated shockwaves focused onto the stone.

The aim is to fragment the calculus into smaller pieces that can subsequently pass through the urinary tract.

Advantages

  • Non-invasive
  • Usually rapid recovery
  • No incision
  • Useful for appropriately selected renal stones

Limitations

Success depends on:

  • Stone size
  • Location
  • Density
  • Composition
  • Skin-to-stone distance
  • Renal anatomy

Hard stones such as calcium oxalate monohydrate, brushite and cystine stones may be less responsive.

More than one treatment session may be required.

3. Flexible Ureteroscopy and Laser Lithotripsy

A fine flexible telescope is passed through the urethra and bladder, up the ureter and into the kidney.

There are no external incisions.

The stone can then be fragmented or dusted using a laser, with larger fragments removed using tiny retrieval baskets.

Advantages

  • Minimally invasive
  • High stone clearance rates for appropriately selected stones
  • Can treat stones resistant to shockwave therapy
  • Allows direct visualisation
  • Suitable for many locations within the kidney

Possible disadvantages

  • Requires anaesthesia
  • Temporary ureteric stenting may be required
  • Stent discomfort
  • Bleeding or infection
  • Ureteric injury is uncommon but possible
  • Occasionally a second procedure is required

4. Percutaneous Nephrolithotomy

PCNL involves creating a small tract through the skin directly into the kidney.

It is particularly useful for:

  • Large renal calculi
  • Staghorn stones
  • Complex stones
  • Large-volume infection stones
  • Stones unlikely to respond adequately to less invasive techniques

Current EAU guidance recommends PCNL as the first-line treatment for renal stones larger than 2 cm in most suitable patients.

PCNL generally provides excellent clearance of large stone burdens but is more invasive than ureteroscopy or shockwave treatment.

Potential complications include bleeding, infection, injury to surrounding structures and the need for additional procedures.

5. Dissolution Therapy

This option is mainly relevant to uric acid stones.

Urinary alkalinisation can gradually dissolve the stone, potentially avoiding surgery.

Treatment requires:

  • Correct identification or strong suspicion of uric acid composition
  • Regular urine pH monitoring
  • Appropriate alkalinising medication
  • Follow-up imaging
  • Patient compliance

It is important not to assume that every radiolucent stone is uric acid, and treatment should be supervised appropriately.

Choosing the Right Treatment

There is no single “best” kidney stone operation.

The appropriate treatment depends on a combination of:

Stone factors

  • Size
  • Number
  • Location
  • Composition
  • Density
  • Previous growth

Kidney factors

  • Anatomy
  • Obstruction
  • Infection
  • Renal function

Patient factors

  • Symptoms
  • Medical conditions
  • Anticoagulant therapy
  • Previous stone procedures
  • Occupation
  • Travel requirements
  • Personal preference

Two patients with apparently similar 10 mm stones may therefore receive quite different recommendations.

Preventing the Next Kidney Stone

Removing a stone solves today’s problem.

Preventing another stone solves tomorrow’s problem.

Patients with recurrent stones, multiple stones, bilateral stones, unusual stone composition, young age at presentation or other high-risk features may benefit from metabolic investigation.

This may include blood testing and 24-hour urine collections assessing factors such as:

  • Urine volume
  • Calcium
  • Oxalate
  • Citrate
  • Uric acid
  • Sodium
  • Magnesium
  • Urinary pH

Stone analysis is particularly valuable whenever a stone can be retrieved. Current EAU guidance recommends reliable stone analysis and basic metabolic evaluation for stone formers, with specific metabolic assessment for high-risk patients.

General Kidney Stone Prevention

Although prevention should ultimately be tailored to stone composition, several principles apply to many stone formers.

Drink more water

Maintaining generous urine output dilutes the substances responsible for crystal formation.

Water remains wonderfully unexciting and remarkably effective.

Reduce excessive salt intake

High sodium intake can increase urinary calcium excretion and contribute to calcium stone formation.

Maintain normal dietary calcium

Patients with calcium stones should not automatically eliminate calcium-containing foods.

A balanced dietary calcium intake may actually reduce intestinal oxalate absorption.

Moderate excessive animal protein

Large amounts of meat and other purine-rich foods may contribute to increased urinary uric acid and more acidic urine in susceptible individuals.

Maintain a healthy weight

Obesity and metabolic syndrome are particularly associated with uric acid stone formation.

Investigate recurrent stones

Repeatedly removing stones without investigating why they keep forming can become a rather expensive game of geological whack-a-mole.

Can Medication Prevent Kidney Stones?

Yes, in appropriately selected patients.

Depending on the metabolic abnormality and stone composition, preventive medication may include:

  • Potassium citrate
  • Thiazide or thiazide-like medication
  • Allopurinol
  • Urinary alkalinising therapy
  • Tiopronin for selected cystinuria patients

Medication should ideally be guided by stone analysis, blood investigations and, when indicated, 24-hour urine testing rather than prescribed indiscriminately.

The Bottom Line

A kidney stone is not simply a kidney stone.

A calcium oxalate stone, uric acid stone, infection stone and cystine stone may look similar on a scan, but they can have very different causes and require very different long-term strategies.

Modern kidney stone management combines:

accurate imaging + appropriate stone removal + stone analysis + metabolic investigation + prevention.

Treatment may range from simple surveillance through to shockwave lithotripsy, flexible ureteroscopy and laser treatment, PCNL or, in selected uric acid stones, medical dissolution therapy.

The ultimate aim is not simply to leave the operating theatre stone-free.

It is to keep the patient stone-free.

When Should You See a Urologist?

Consider urological assessment if you have:

  • Recurrent kidney stones
  • Persistent loin or flank pain
  • Blood in the urine
  • Recurrent urinary infections
  • A stone associated with urinary obstruction
  • Increasing stone size on surveillance imaging
  • Multiple or bilateral kidney stones
  • A large renal calculus
  • Previous complex stone surgery

Severe pain associated with fever, chills or feeling systemically unwell requires urgent medical assessment, as an infected obstructed kidney can be a medical emergency.

This information is intended for general patient education and does not replace individual medical assessment. The appropriate investigation, surveillance and treatment of kidney stones should be tailored to the individual patient.

This blog is aligned with the current 2026 EAU Urolithiasis Guidelines, including the updated recommendations on stone composition, renal stone treatment and metabolic prevention.

EAU Guidelines on Urolithiasis

Calcium Oxalate Kidney Stones: Treatment, Surgery and Prevention

/0 Comments/in , /by

Calcium oxalate stones are the most common type of urinary tract stone. Although the name may suggest that eating too much calcium is the problem, the biology is considerably more complicated. Stone formation reflects the interaction between urine volume, calcium, oxalate, citrate, sodium, dietary factors, genetics and, in some patients, underlying metabolic or gastrointestinal conditions.

The encouraging news is that most calcium oxalate stones can be treated effectively, and the risk of forming further stones can often be substantially reduced with appropriate investigation and prevention.

This guide explains conservative management, imaging, surgical treatment, ureteric pre-stenting, laser fragmentation, recovery and long-term prevention.

What is a calcium oxalate stone?

Calcium oxalate crystals form when urine becomes sufficiently concentrated with calcium and oxalate for crystals to develop and grow.

Two principal forms occur:

  • Calcium oxalate monohydrate, which tends to be harder and more resistant to shock-wave fragmentation.
  • Calcium oxalate dihydrate, which is generally more readily fragmented.

Importantly, calcium oxalate stones cannot usually be dissolved with medication. This differs from uric acid stones, which can sometimes be dissolved by alkalinising the urine.

Treatment therefore involves either allowing a suitable stone to pass naturally, monitoring an asymptomatic stone, or physically removing or fragmenting it when intervention is required.

How do calcium oxalate stones present?

A stone sitting quietly inside the kidney may produce no symptoms at all and may be discovered incidentally during imaging performed for another reason.

When a stone moves into the ureter, symptoms can be dramatic and may include:

  • Severe loin or flank pain
  • Pain radiating towards the groin or testicle/labia
  • Nausea and vomiting
  • Blood in the urine
  • Urinary frequency or urgency
  • Burning with urination
  • Restlessness during an episode of renal colic

Fever or chills associated with an obstructing stone require urgent medical assessment. An infected obstructed kidney is a urological emergency and may require immediate drainage with a ureteric stent or nephrostomy rather than definitive stone treatment at that time.

Imaging calcium oxalate stones

CT scan

A non-contrast CT of the kidneys, ureters and bladder (CT KUB) is generally the most accurate investigation for suspected urinary tract calculi.

CT provides valuable information about:

  • Stone size
  • Exact location
  • Number of stones
  • Degree of urinary obstruction
  • Hydronephrosis
  • Stone density
  • Anatomy relevant to treatment planning

Stone density is measured in Hounsfield units (HU) and can sometimes help predict how readily a stone may fragment with shock-wave treatment.

The major disadvantage of CT is radiation exposure, although modern low-dose CT protocols can substantially reduce the radiation dose.

Ultrasound

Ultrasound avoids radiation and is particularly useful for:

  • Follow-up
  • Monitoring known renal stones
  • Detecting hydronephrosis
  • Pregnancy
  • Patients requiring repeated imaging

Its disadvantage is that small ureteric stones can be missed, and measurement of stone size is generally less accurate than CT.

Plain X-ray – KUB

Most calcium oxalate stones are radiopaque and therefore visible on a plain abdominal X-ray.

KUB imaging can consequently be useful for monitoring selected stones, particularly following treatment or when considering shock-wave lithotripsy.

Does every calcium oxalate stone require surgery?

No.

A small stone without infection, significant obstruction or uncontrolled pain can frequently be managed conservatively.

Small asymptomatic stones within the kidney may also simply be monitored.

Observation is reasonable when the potential risks and inconvenience of treatment exceed the likely benefit.

Current European guidelines recognise active surveillance as an option for selected asymptomatic renal stones, although stone growth, development of symptoms or obstruction may eventually prompt intervention.

Conservative management

For a small ureteric stone that is likely to pass spontaneously, treatment may include:

Hydration

Maintain normal good hydration. Trying to “flush” a painful obstructing stone through by drinking enormous quantities of water is generally unnecessary and can actually worsen discomfort.

Pain relief

Anti-inflammatory medication is frequently particularly effective for renal colic, provided there are no medical contraindications.

Additional analgesia or anti-nausea medication may occasionally be required.

Medical expulsive therapy

An alpha-blocker such as tamsulosin may be prescribed in selected patients to facilitate passage of a ureteric stone.

The greatest benefit appears to occur with distal ureteric stones larger than approximately 5 mm, although its use for stone passage is off-label in many jurisdictions.

Straining the urine

Catching the stone is surprisingly useful. Sending a retrieved stone for laboratory analysis confirms its composition and helps direct prevention.

The small pebble that caused an astonishing amount of trouble can therefore become an important diagnostic specimen.

When should a stone be removed?

Intervention may be recommended when there is:

  • Persistent or recurrent pain
  • Failure of the stone to progress
  • Significant urinary obstruction
  • Deterioration in renal function
  • Recurrent urinary infection
  • Increasing stone size
  • A low likelihood of spontaneous passage
  • A large renal stone burden
  • Occupational or lifestyle reasons where an unpredictable episode of renal colic would be problematic

Treatment is individualised according to stone size, location, density, renal anatomy, symptoms and patient preference.

Surgical treatment options

1. Extracorporeal Shock-Wave Lithotripsy – ESWL/SWL

Shock-wave lithotripsy focuses externally generated shock waves onto the stone, breaking it into smaller fragments that can subsequently pass through the urinary tract.

Advantages

  • No incision
  • Usually relatively rapid recovery
  • May avoid ureteroscopy
  • Useful for appropriately selected renal and ureteric stones

Disadvantages

  • Not all calcium oxalate stones fragment equally well
  • Hard calcium oxalate monohydrate stones may be resistant
  • Several treatment sessions may be required
  • Fragments still need to pass down the ureter
  • Residual fragments can remain
  • Temporary renal colic can occur
  • Less effective for some lower-pole renal stones and larger stones

The success of SWL is strongly influenced by stone size, location, composition, patient anatomy and stone hardness.

2. Ureteroscopy and laser lithotripsy

Ureteroscopy has transformed modern stone treatment.

A fine telescope is passed through the natural urinary tract:

urethra → bladder → ureter → kidney

There is therefore no external surgical incision.

Rigid or semi-rigid ureteroscopy can be used for ureteric stones, while flexible ureteroscopy allows access to stones within the kidney.

Laser fragmentation

Once the stone is identified, laser energy is delivered through an extremely fine fibre passed through the ureteroscope.

Modern systems include:

  • Holmium laser
  • Thulium fibre laser (TFL)

Both are highly effective technologies for flexible ureteroscopic stone treatment, and contemporary European guidelines recommend Ho or TFL for ureteroscopic laser lithotripsy.

The stone can be treated using several strategies.

Fragmentation and extraction

The stone is divided into several pieces, which are removed using a small basket.

Dusting

The laser progressively converts the stone into extremely small particles or “dust”, allowing much of the material to pass spontaneously.

Pop-dusting or further fragmentation

Larger fragments can be further reduced until they are sufficiently small to pass or be extracted.

Advantages of ureteroscopy and laser treatment

Ureteroscopy provides:

  • Direct visualisation of the stone
  • High stone-clearance rates
  • Treatment of stones resistant to shock-wave lithotripsy
  • Access to most areas of the ureter and kidney
  • Immediate fragmentation
  • Ability to retrieve fragments for stone analysis
  • No external incision
  • Usually short hospitalisation

Compared with shock-wave lithotripsy, ureteroscopy generally offers a greater likelihood of becoming stone-free after a single procedure, although this comes at the price of greater invasiveness and a somewhat higher complication rate.

Possible complications of ureteroscopy

Although generally safe, complications can include:

  • Blood in the urine
  • Urinary infection
  • Pain
  • Ureteric swelling
  • Temporary difficulty passing urine
  • Residual stone fragments
  • Need for repeat ureteroscopy
  • Ureteric perforation
  • Ureteric stricture
  • Sepsis

Major ureteric injury is uncommon.

The EAU reports overall ureteroscopy complication rates of approximately 4–25%, with most complications being minor. Urosepsis is an important but uncommon serious complication.

Pre-operative urine testing and treatment of urinary infection are therefore important components of safe stone surgery.

What is pre-stenting?

A ureteric stent is a thin flexible tube extending from the kidney to the bladder.

Sometimes the ureter is too narrow to safely introduce the instruments required for flexible ureteroscopy.

Instead of forcing access, a temporary stent can be inserted.

The stent gently allows passive dilatation of the ureter before definitive surgery.

Ureteroscopy is then performed at a later date, commonly after the ureter has had time to accommodate the stent.

Does everyone need pre-stenting?

No.

Routine pre-stenting before ureteroscopy is not necessary.

However, pre-stenting can be useful when:

  • The ureter is particularly narrow
  • Previous access has been unsuccessful
  • A large renal stone burden is anticipated
  • An access sheath is likely to be required
  • Staged ureteroscopy is planned
  • Emergency drainage was previously required because of infection or obstruction

Evidence suggests that pre-stenting can improve access and may improve stone-free outcomes for renal stones, although the benefit is less clear for ureteric stones.

The price of this convenience is that the patient has to live temporarily with a ureteric stent.

Ureteric stent side effects

Stents are useful pieces of equipment, but they rarely win popularity contests.

Possible symptoms include:

  • Urinary frequency
  • Urgency
  • Bladder discomfort
  • Burning during urination
  • Blood in the urine
  • Flank discomfort during urination
  • Pelvic or groin discomfort

Symptoms disappear after the stent is removed.

Alpha-blocker medication can reduce stent-related symptoms in selected patients.

Is a stent required after laser treatment?

Not always.

After straightforward uncomplicated ureteroscopy with complete stone clearance and no ureteric trauma, a postoperative stent may not be necessary.

A stent is more likely to be placed following:

  • Difficult ureteric access
  • Significant ureteric swelling
  • Ureteric trauma
  • Large stone burden
  • Residual fragments
  • Bleeding
  • Infection concerns
  • Prolonged surgery
  • Staged treatment

Current evidence supports avoiding routine postoperative stenting following uncomplicated ureteroscopy.

3. Percutaneous nephrolithotomy – PCNL

Very large renal stones are usually better approached directly through the back rather than attempting to remove the entire stone burden through the ureter.

PCNL involves creating a small tract through the skin into the kidney, through which instruments can fragment and extract the stone.

PCNL remains the standard treatment for large renal calculi, particularly stones greater than approximately 2 cm and complex or staghorn stone burdens.

Advantages

  • Excellent clearance of large stone burdens
  • Large fragments can be removed directly
  • Often more efficient than multiple ureteroscopies for large stones

Disadvantages

  • More invasive
  • Bleeding risk
  • Infection/sepsis risk
  • Longer recovery than routine ureteroscopy
  • Potential need for nephrostomy drainage
  • Rare injury to surrounding structures

Recovery after ureteroscopy and laser lithotripsy

Most patients recover relatively quickly.

It is common to experience:

  • Mild burning when passing urine
  • Pink or blood-stained urine
  • Urinary frequency
  • Mild flank discomfort
  • Stent-related symptoms

Many patients return to light activities within several days, although recovery depends on the extent of the procedure and whether a stent remains.

Heavy physical activity may need to be avoided for a short period.

Patients should seek medical attention for:

  • Fever or chills
  • Increasing severe pain
  • Persistent vomiting
  • Inability to pass urine
  • Heavy persistent bleeding
  • Feeling systemically unwell

Have we finished once the stone has gone?

Not quite.

Removing a stone treats today’s stone.

Preventing another one requires identifying why it formed.

This distinction is important because calcium oxalate stone disease can recur.

Current EAU data suggest approximately 26% of first-time stone formers experience recurrence within five years, while a smaller group develops highly recurrent disease.

Patients with recurrent stones, multiple stones, bilateral stones, young-onset stone disease or particular metabolic risk factors deserve more detailed investigation.

Metabolic investigation

Depending on the clinical situation, evaluation may include:

Blood tests

  • Calcium
  • Creatinine and renal function
  • Electrolytes
  • Uric acid
  • Bicarbonate
  • Parathyroid hormone when indicated

Stone analysis

Any retrieved stone should ideally be sent for formal analysis.

24-hour urine collection

This can measure:

  • Total urine volume
  • Calcium
  • Oxalate
  • Citrate
  • Sodium
  • Uric acid
  • Urinary pH
  • Other relevant metabolic parameters

The results allow prevention to be targeted rather than relying on a generic “kidney stone diet”.

Preventing calcium oxalate stones

1. Drink more fluid

For many patients, the single most important intervention is increasing urine volume.

Rather than concentrating stone-forming chemicals into a small volume of urine, additional fluid keeps them diluted.

Water should generally form the majority of fluid intake.

The required intake varies with climate, exercise, occupation and perspiration. Someone working outdoors during an Australian summer may require considerably more fluid than someone sitting in an air-conditioned office.

2. Do not automatically restrict calcium

This is one of the most common misconceptions about calcium oxalate stones.

Calcium in the stone does not mean calcium should disappear from the diet.

Normal dietary calcium is generally desirable because calcium within the intestine binds dietary oxalate. This reduces oxalate absorption and consequently reduces the amount reaching the urine.

The EAU specifically advises that dietary calcium should generally not be restricted unless there is a particular reason to do so.

3. Reduce excessive salt intake

A high sodium intake increases urinary calcium excretion.

Reducing dietary salt can therefore help reduce urinary calcium and forms an important part of recurrence prevention.

Pay particular attention to hidden salt in:

  • Processed foods
  • Takeaway meals
  • Processed meats
  • Sauces
  • Packaged snacks
  • Some breads and prepared foods

4. What about oxalate?

Traditional advice often involved handing patients an intimidating list of foods containing oxalate.

Contemporary Australian CARI guidance takes a more nuanced approach and recommends against a blanket low-oxalate diet for calcium oxalate stone prevention. Instead, maintaining appropriate dietary calcium and addressing excessive intake in patients with hyperoxaluria may be more useful.

Patients with documented high urinary oxalate may need individualised dietary advice.

5. Avoid excessive vitamin C supplementation

Vitamin C can be metabolised to oxalate.

For recurrent calcium oxalate stone formers, particularly those with elevated urinary oxalate, very high-dose vitamin C supplements should generally be avoided unless there is a specific medical indication.

6. Moderate excessive animal protein

Large amounts of animal protein can alter urinary chemistry in ways that encourage stone formation, including reducing urinary citrate and increasing acid and uric acid loads.

The aim is generally moderation rather than elimination.

 

7. What about cola and other soft drinks?

Patients frequently ask whether cola-type soft drinks contribute to kidney stones.

The answer is more nuanced than simply blaming carbonation. The bubbles themselves are not the problem. Of greater relevance are the acid composition, sugar content and the fact that regular soft-drink consumption can displace water and other more favourable fluids from the diet.

Cola-type drinks

Many dark cola-style beverages contain phosphoric acid. High consumption of these beverages has been associated in some studies with an increased risk of stone formation or recurrence.

One clinical trial examining patients with recurrent stones found that reducing soft-drink consumption lowered recurrence, with the benefit appearing particularly relevant among people whose preferred beverages were acidified with phosphoric acid.

This does not mean that an occasional cola-type drink will automatically produce a kidney stone. The concern is frequent or high-volume consumption, particularly in someone already predisposed to recurrent stones.

Sugar-sweetened soft drinks

Regular consumption of sugar-sweetened beverages may also be undesirable for stone prevention.

Large amounts of sugar, particularly fructose-containing sweeteners, may alter urinary chemistry and have been associated with a greater risk of kidney stone formation in observational studies.

There is another very practical issue: every large glass of soft drink may be replacing a glass of water.

For a recurrent stone former, that is not an especially favourable trade.

Are sugar-free versions better?

Removing sugar eliminates one potential problem, but it does not necessarily make a cola-type beverage ideal for someone with recurrent stones.

Sugar-free varieties may still contain phosphoric acid, and frequent consumption may still replace water in the daily fluid intake.

What should I drink instead?

For most calcium oxalate stone formers:

Water remains the preferred everyday drink.

Citrus-containing fluids may also be useful because citrate is a natural inhibitor of calcium stone formation, although the citrate content and sugar load of different beverages vary considerably.

The practical message is therefore not that a patient can never have another soft drink. Rather:

make water the routine drink and soft drinks the occasional one.

The kidneys are generally more interested in what happens every day than what happens at the occasional barbecue.

Preventative medication

Medication is not required for every patient.

Treatment should ideally be directed by stone analysis, metabolic assessment and 24-hour urine results.

Potassium citrate

Potassium citrate increases urinary citrate.

Citrate is helpful because it binds calcium and inhibits calcium crystal formation.

It can be particularly useful in patients with hypocitraturia.

Potential side effects include:

  • Gastrointestinal discomfort
  • Nausea
  • Diarrhoea
  • Elevated blood potassium in susceptible patients

It requires particular caution in patients with impaired renal function or medications that increase serum potassium.

Current Australian CARI guidance considers potassium citrate an important pharmacological option for prevention of recurrent stones when appropriately indicated.

Thiazide and thiazide-like diuretics

These medications reduce urinary calcium excretion and may be considered in patients with persistent hypercalciuria despite appropriate dietary measures.

Potential side effects include:

  • Low blood pressure
  • Dizziness
  • Low sodium
  • Low potassium
  • Increased uric acid
  • Changes in glucose metabolism

The evidence surrounding thiazides has become more nuanced following recent clinical trials, and treatment should therefore be individualised rather than automatically prescribed to every recurrent calcium stone former.

Allopurinol

Allopurinol is not a routine treatment for every calcium oxalate stone former.

It may have a role in selected patients with hyperuricosuria or other specific metabolic abnormalities.

Treatment should be guided by appropriate biochemical evaluation rather than simply by the presence of a calcium oxalate stone.

The pros and cons of the main approaches

Treatment Advantages Disadvantages
Observation No surgery or anaesthetic Stone may grow, move or cause future symptoms
Medical expulsive therapy May help selected ureteric stones pass Not suitable for infection, significant obstruction or large stones
Shock-wave lithotripsy Non-invasive, relatively quick recovery May require repeat treatment; fragments must pass; harder stones may resist fragmentation
Ureteroscopy + laser High clearance rate, direct visual treatment, no skin incision Anaesthetic, possible stent, infection and ureteric injury risks
PCNL Excellent treatment for large renal stone burdens More invasive with greater bleeding and recovery considerations
Preventative medication Can significantly alter relevant urinary risk factors Requires correct patient selection, monitoring and long-term adherence

How effective is treatment?

There is no single “best” treatment for every calcium oxalate stone.

A 5 mm distal ureteric stone, a 12 mm lower-pole renal stone and a 30 mm renal pelvic stone may all be made from exactly the same material, yet require completely different management.

The objective is therefore not simply to treat calcium oxalate, but to treat:

the right stone, in the right patient, with the least invasive treatment likely to achieve reliable clearance.

For appropriately selected ureteric and renal stones, modern flexible ureteroscopy and laser lithotripsy provide excellent clearance with rapid recovery. Larger stone burdens may be better managed with PCNL, while smaller asymptomatic stones may need nothing more than surveillance.

Reducing the risk of another stone

For most calcium oxalate stone formers, prevention revolves around a few principles:

  1. Maintain a high urine volume.
  2. Keep normal dietary calcium rather than unnecessarily restricting it.
  3. Reduce excessive dietary sodium.
  4. Avoid excessive animal protein and high-dose vitamin C supplementation.
  5. Investigate recurrent stone formers metabolically.
  6. Use potassium citrate, thiazide therapy or other preventative medication when a specific metabolic indication exists.
  7. Continue appropriate imaging surveillance.

Australian CARI guidelines emphasise nutrition therapy before pharmacological treatment for many stone formers, with earlier medication appropriate for selected high-risk metabolic abnormalities or patients with a high symptom burden.

The bottom line

Calcium oxalate stones are extremely common, but their treatment has become increasingly precise.

Small uncomplicated stones can often be observed or allowed to pass naturally. Stones requiring treatment can be managed with shock-wave lithotripsy, ureteroscopy with laser fragmentation, or PCNL, depending primarily on their size and location.

Ureteroscopic laser treatment offers excellent access to the urinary tract without an external incision, and modern holmium and thulium fibre lasers can fragment even very hard calcium oxalate calculi. Pre-stenting is useful in selected patients but is not routinely necessary.

Perhaps the most important message comes after the operation: removing the stone is only half the job.

Stone analysis, appropriate imaging and metabolic evaluation can identify why stones are forming. Increased fluid intake, sensible dietary modification and targeted preventative medication can then reduce the likelihood that another small crystal grows into the next large problem.

This information is intended for general patient education and does not replace individual assessment by a urologist. Management should be tailored to stone size and location, kidney function, infection risk, medical history and individual metabolic findings.

So, if you are in trouble with ureteric colic, attend your local Emergency Department for acute management and assessment for urgent stent placement. Further management will be discussed with you thereafter. Ask your GP for a referral to see a Urologist.

Further reading

Dissolution Therapy for Uric Acid Kidney Stones: Can You Really Dissolve a Stone?

/0 Comments/in , , /by

Most kidney stones need to be passed, fragmented or surgically removed. Uric acid stones are different.

Unlike calcium-based stones, a true uric acid stone can often be chemically dissolved inside the urinary tract simply by changing the acidity of the urine. This treatment is known as oral dissolution therapy, urinary alkalinisation or oral chemolysis.

For appropriately selected patients, it can mean avoiding ureteroscopy, laser treatment, shock-wave lithotripsy or percutaneous surgery altogether.

What is a uric acid stone?

Uric acid stones account for approximately 10% of urinary stones, although their frequency varies considerably between populations. They tend to develop when the urine remains persistently acidic, particularly at a urinary pH below approximately 5.5.

Risk factors include:

  • persistently acidic urine
  • low fluid intake and concentrated urine
  • high intake of animal protein and purine-rich foods
  • gout or elevated uric acid
  • obesity and metabolic syndrome
  • diabetes and insulin resistance
  • chronic diarrhoea or intestinal disease
  • high urinary uric acid excretion
  • some haematological disorders and chemotherapy

Importantly, many people who form uric acid stones do not have dramatically elevated blood or urinary uric acid. The major problem is often simply that their urine is too acidic. This is why alkalinising the urine is usually more important than immediately prescribing allopurinol.

Why can uric acid stones be dissolved?

Uric acid is poorly soluble in acidic urine. As urinary pH rises, uric acid becomes increasingly ionised and substantially more soluble.

Think of the stone as a sugar cube sitting in the wrong cup of tea. Change the chemistry of the surrounding fluid and the solid material can gradually return into solution.

The aim of dissolution therapy is therefore to raise the urinary pH sufficiently and keep it elevated throughout the day, allowing the surface of the stone to gradually dissolve.

Current European Association of Urology guidance recommends oral chemolysis using alkaline citrate or sodium bicarbonate, with urine pH generally adjusted to approximately 7.0–7.2 during active dissolution therapy.

How is dissolution therapy performed?

The most commonly used medication is potassium citrate.

Alternative alkalinising agents include:

  • sodium bicarbonate
  • sodium citrate
  • other citrate preparations

Potassium citrate is generally preferred when appropriate because sodium-containing preparations increase sodium intake and may increase urinary calcium excretion. Sodium-based treatment can nevertheless be useful when potassium therapy is unsuitable, particularly when there is concern regarding hyperkalaemia.

The exact dose needs to be individualised according to kidney function, serum electrolytes and, most importantly, the patient’s urinary pH response.

Monitoring your urine pH

This is a crucial part of treatment.

Patients are usually asked to measure their urinary pH at home using suitable pH strips or a pH meter, often at several points during the day.

The dose of alkalinising medication can then be adjusted to keep the urine within the desired range. The EAU specifically recommends teaching patients to monitor their urine pH and modify alkalinising medication accordingly.

The objective is not simply to swallow tablets. It is to achieve and maintain the correct urinary pH.

How effective is dissolution therapy?

When the stone really is composed predominantly of uric acid and urinary alkalinisation is successfully achieved, dissolution therapy can be remarkably effective.

A systematic review involving 1,075 patients reported:

Outcome Approximate rate
Complete dissolution 61.7%
Partial dissolution 19.8%
Complete or partial response 80.5%
Treatment discontinued 10.2%
Required surgical intervention 15.7%

These figures are encouraging, but they also make an important point: dissolution therapy does not work for everyone.

Success depends heavily on correct stone identification, adequate urinary alkalinisation, patient compliance and the size and burden of the stones.

How quickly will the stone disappear?

This varies considerably.

Small stones may respond relatively quickly, while larger stones can require treatment over several months. Dissolution is generally a gradual process rather than an overnight disappearing act.

One clinical series assessing stone volume found that response was associated with achieving a higher urinary pH during treatment, reinforcing the importance of adequate alkalinisation.

Follow-up imaging is therefore important to determine whether the stone is shrinking rather than simply assuming that treatment is working.

How do we know that the stone is uric acid?

This is one of the most important questions.

There is little benefit in trying to dissolve a calcium oxalate stone with urinary alkalinisation. It will remain stubbornly unimpressed.

Evidence suggesting a uric acid stone includes:

  • previous analysis confirming a uric acid stone
  • persistently acidic urinary pH
  • radiolucency on plain X-ray
  • relatively low density on non-contrast CT
  • appropriate clinical and metabolic risk factors

Dual-energy CT can sometimes help differentiate uric acid from non-uric-acid stones.

Stone composition should therefore be assessed as accurately as possible before embarking on prolonged dissolution therapy.

Advantages of dissolution therapy

The biggest advantage is obvious: it is non-invasive.

Successful treatment may avoid anaesthesia and procedures such as ureteroscopy, laser lithotripsy, shock-wave lithotripsy or PCNL.

Other potential advantages include:

  • no surgical incision
  • no instrumentation of the urinary tract
  • usually no hospital admission
  • avoidance of anaesthetic risk
  • potentially useful for patients with significant medical comorbidities
  • treatment can simultaneously address the metabolic environment responsible for future uric acid stones
  • relatively inexpensive compared with surgery
  • can potentially treat multiple uric acid stones simultaneously

For the right patient, dissolution therapy can turn a surgical problem into a metabolic one.

What are the disadvantages?

The trade-off is that dissolution therapy requires time, patience and active participation.

Patients need to take medication consistently, maintain good fluid intake, monitor urinary pH and attend follow-up investigations.

Other disadvantages include:

  • dissolution can take weeks or months
  • treatment may fail
  • the stone may only partially dissolve
  • repeated imaging may be required
  • incorrectly identified non-uric-acid stones will not dissolve
  • excessively alkaline urine can encourage formation of calcium phosphate stones
  • patients with obstruction or infection may require urgent intervention rather than simply waiting for dissolution

In the systematic review discussed above, approximately 15.7% of patients ultimately required an intervention despite attempting dissolution therapy.

Side effects of potassium citrate

Potassium citrate is generally well tolerated, but side effects can occur.

The most common are gastrointestinal and may include:

  • nausea
  • abdominal discomfort
  • bloating
  • diarrhoea
  • vomiting

Taking the medication with food may improve gastrointestinal tolerance.

A more important potential complication is hyperkalaemia, meaning an excessively high potassium concentration in the blood.

This is particularly relevant in patients with:

  • impaired kidney function
  • medications that increase potassium
  • significant cardiac disease
  • other conditions affecting potassium regulation

For this reason, kidney function and electrolytes may need monitoring during therapy.

What about sodium bicarbonate?

Sodium bicarbonate can also effectively alkalinise the urine and is an alternative when potassium citrate is unsuitable.

However, the additional sodium load can be undesirable in patients with conditions such as hypertension, fluid retention or heart failure. Sodium-containing alkali may also increase urinary calcium excretion, which is one reason potassium citrate is generally preferred when clinically appropriate.

Can the urine become too alkaline?

Yes.

More alkaline is not endlessly better.

Although increasing urinary pH improves uric acid solubility, excessive alkalinisation can increase the risk of calcium phosphate stone formation. The EAU therefore recommends targeting rather than indiscriminately increasing urinary pH.

This is why home pH monitoring is so useful.

The aim is controlled chemistry, not turning the bladder into a miniature alkaline swimming pool.

What if the stone is obstructing the kidney?

An obstructed kidney requires more caution.

If a uric acid stone is causing significant obstruction, particularly in the presence of infection, deteriorating renal function or uncontrolled symptoms, simply waiting for the stone to dissolve may be inappropriate.

An infected obstructed urinary system is a urological emergency and requires urgent drainage.

Where an obstructing uric acid stone is otherwise suitable for dissolution, urinary drainage with a ureteric stent or nephrostomy may sometimes be performed first, followed by alkalinisation. The EAU recommends oral chemolysis together with urinary drainage where uric acid stones are obstructing the collecting system.

Does allopurinol dissolve uric acid stones?

Not directly in the same way that alkalinisation does.

Allopurinol reduces the production of uric acid and is particularly useful in patients with hyperuricosuria, gout or continued uric acid stone formation despite appropriate management.

However, most uric acid stone formers have excessively acidic urine as the dominant problem. The AUA therefore recommends potassium citrate as first-line therapy for urinary alkalinisation rather than routinely using allopurinol as first-line treatment for every patient with uric acid stones.

Allopurinol may be added when there is significant hyperuricosuria or recurrent stone formation despite appropriate urinary alkalinisation. The EAU similarly recommends allopurinol for hyperuricosuric urate stone formers.

Preventing the stone from coming back

Dissolving the existing stone is only half the job.

Uric acid stone formers are considered at high risk of recurrence, so the underlying metabolic environment should also be addressed.

Long-term prevention may include maintaining a generous fluid intake, moderating excessive animal protein and purine intake, weight and metabolic health management, continued urinary alkalinisation when indicated, and treatment of hyperuricosuria where appropriate.

A metabolic stone assessment, often including blood tests and 24-hour urine collections, can help identify the factors driving recurrent stone formation.

Dissolution therapy versus surgery

There is no universal winner.

Dissolution therapy is particularly attractive when:

  • the stone is highly likely to be uric acid
  • symptoms are controlled
  • there is no untreated infection
  • renal function is satisfactory
  • immediate stone clearance is unnecessary
  • the patient can reliably monitor urinary pH and attend follow-up

Surgical treatment may be preferable when:

  • the diagnosis of uric acid stone is uncertain
  • the stone is causing significant or persistent obstruction
  • infection is present
  • pain is difficult to control
  • rapid stone clearance is required
  • the stone fails to shrink despite adequate alkalinisation
  • the patient prefers definitive treatment

The bottom line

Uric acid stones have one rather convenient weakness: their chemistry can be used against them.

By raising urinary pH with medications such as potassium citrate, genuine uric acid calculi can often be progressively dissolved without an operation. Published evidence suggests that approximately 80% of appropriately treated patients achieve at least partial dissolution, although complete dissolution occurs in a smaller proportion and some patients will ultimately require surgery.

Successful treatment depends on three things: correctly identifying the stone, achieving the appropriate urinary pH, and monitoring the response.

For selected patients, dissolution therapy offers something unusual in stone surgery: rather than breaking the stone, extracting it or blasting it with a laser, we may simply persuade it to disappear.

This information is intended for general patient education and does not replace individual assessment by a urologist. Treatment and urinary pH targets should be individualised, particularly in patients with renal impairment, infection, obstruction or electrolyte abnormalities.

Robotic-Assisted Enucleation of the Large Benign Prostate / Robotic-Assisted Simple Prostatectomy RASP

/0 Comments/in , /by

A modern surgical option for very large benign prostate enlargement

Benign prostatic hyperplasia (BPH), or benign prostate enlargement, becomes increasingly common as men age. For many men, symptoms can initially be controlled with medication or minimally invasive treatments. However, when the prostate becomes very large, simply creating a small channel through the prostate may not provide the durable result required.

Robotic-assisted simple prostatectomy (RASP), sometimes described as robotic-assisted adenoma enucleation, is designed to remove the bulk of the obstructing benign prostate tissue while leaving the outer prostate capsule behind.

Importantly, this is not the same operation as a robotic radical prostatectomy for prostate cancer. In a radical prostatectomy, the entire prostate and seminal vesicles are removed. In robotic simple prostatectomy, only the enlarged central adenoma responsible for urinary obstruction is removed.

Current guidelines recognise robotic-assisted simple prostatectomy as an established surgical option for men with large to very large prostates.

Why does a large prostate cause problems?

The prostate surrounds the urethra immediately below the bladder.

As benign prostate tissue enlarges, it can compress and distort the urethra. The bladder then has to work increasingly hard to push urine through this narrowed channel.

Symptoms may include:

  • Weak urinary stream
  • Hesitancy or difficulty starting urination
  • Straining
  • Intermittent urinary flow
  • A feeling that the bladder has not emptied properly
  • Frequent urination
  • Urgency
  • Getting up repeatedly at night to urinate
  • Acute or chronic urinary retention
  • Recurrent urinary infections
  • Bladder stones
  • Blood in the urine
  • Progressive deterioration of bladder function
  • In severe cases, obstruction affecting the kidneys

Surgery is particularly appropriate when significant symptoms persist despite conservative or medical therapy, or when BPH produces complications such as recurrent urinary retention, infection, bladder stones, recurrent bleeding or renal impairment.

When is robotic prostate enucleation considered?

Robotic-assisted enucleation is particularly attractive when the prostate is large or very large.

There is no magical prostate volume at which the robot suddenly becomes necessary. Treatment needs to be individualised according to prostate anatomy, symptoms, bladder function, other medical conditions and the surgeon’s expertise.

In practice, robotic simple prostatectomy is most commonly considered for prostates approximately 80–100 mL or larger, and can be particularly useful for extremely large glands well beyond 150–200 mL.

The EAU describes simple prostatectomy as a treatment primarily for substantially enlarged prostates, traditionally above approximately 80–100 mL.

Typical indications include:

  • Severe lower urinary tract symptoms caused by a very large prostate
  • Recurrent urinary retention
  • Dependence on an indwelling or intermittent urinary catheter
  • Failure or intolerance of BPH medications
  • Recurrent bladder infections associated with obstruction
  • Recurrent bleeding from a large vascular prostate
  • Bladder stones associated with prostate obstruction
  • Very high residual urine volumes
  • Progressive bladder dysfunction caused by obstruction
  • Upper urinary tract or renal consequences from longstanding obstruction
  • A very large median lobe protruding into the bladder
  • A very large prostate where conventional TURP would be impractical or require extensive resection

Robotic surgery can also be useful when another bladder procedure, such as removal of large bladder stones or repair of a bladder diverticulum, needs to be performed at the same operation.

How is the operation performed?

The procedure is usually performed under a general anaesthetic using a robotic surgical platform.

Several small incisions are made in the abdomen. Robotic instruments and a high-definition three-dimensional camera are introduced through these ports.

The surgeon remains completely in control of the operation. The robot does not perform the surgery independently. Rather, it translates the surgeon’s hand movements into extremely precise movements of miniature instruments inside the body.

There are several variations of robotic simple prostatectomy, including transvesical, transcapsular, extraperitoneal and newer single-port approaches.

Finding the natural plane

The principle of the operation is beautifully simple.

The enlarged prostate consists of an inner adenoma surrounded by the compressed outer prostate or surgical capsule.

The surgeon identifies the natural anatomical plane between these layers and carefully separates the adenoma from the capsule.

Think of removing the flesh of an orange while deliberately leaving the peel behind. 🍊

The obstructing prostate adenoma is progressively freed from its surrounding capsule and removed.

Bleeding points can be precisely controlled using robotic suturing and cautery. The remaining prostate cavity and bladder are then reconstructed according to the surgical technique being used.

The removed prostate tissue is sent to pathology for examination.

What happens to the prostate afterwards?

The prostate is not completely removed.

The peripheral prostate and capsule remain in the body.

This is important because:

  1. PSA does not normally fall to zero after the operation.
  2. The remaining prostate tissue can still develop prostate cancer in the future.
  3. Appropriate PSA surveillance and prostate cancer screening should therefore continue.

Occasionally, previously unsuspected prostate cancer may also be identified when the removed adenoma is examined by the pathologist.

What happens to urinary flow?

Removing the obstructing adenoma creates a very large channel between the bladder and the remaining prostatic urethra.

Most appropriately selected patients experience substantial improvements in:

  • Urinary flow
  • Bladder emptying
  • Residual urine
  • Urinary symptoms
  • Quality of life

Studies of laparoscopic and robotic simple prostatectomy demonstrate substantial improvements in urinary symptom scores and maximum urinary flow rates.

For a man who has spent years waiting for his bladder to negotiate with a very large prostate, the improvement in flow can be rather dramatic.

The urinary catheter

A urinary catheter is placed during the operation.

This allows urine to drain freely while the bladder and prostate cavity heal. Depending upon the operation and surgeon’s technique, continuous bladder irrigation may initially be used to prevent blood clots accumulating within the bladder.

How long does the catheter stay in?

Catheter duration varies considerably between surgical techniques and centres.

Following conventional robotic simple prostatectomy, a catheter commonly remains for approximately 5–10 days, although some contemporary techniques permit earlier removal.

Recent comparative studies report catheter durations around 5–11 days following RASP, although protocols vary substantially between surgeons and institutions.

Laser enucleation procedures such as HoLEP generally permit earlier catheter removal. A 2026 meta-analysis comparing robotic simple prostatectomy with laser enucleation found that catheterisation was approximately 3.5 days shorter after laser enucleation.

In some patients a cystogram may be performed before catheter removal, particularly when extensive bladder reconstruction has been performed.

What can I expect after catheter removal?

The first few days can be a little lively.

Patients may experience:

  • Urinary frequency
  • Urgency
  • Mild burning
  • Blood in the urine
  • Passing occasional small clots
  • Temporary leakage
  • A sudden improvement in urinary flow

Urinary frequency and urgency can take longer to settle if the bladder has been struggling against obstruction for many years.

Removing the obstruction fixes the prostate problem, but an ageing or overactive bladder does not necessarily receive the memo immediately.

Advantages of robotic-assisted enucleation

For appropriately selected men with very large prostates, potential advantages include:

Removal of a very large amount of obstructing tissue

Rather than simply widening the channel, the procedure anatomically removes most of the transition-zone adenoma.

Suitable for extremely large prostates

The technique is relatively independent of prostate size and can be particularly useful when the prostate is enormous.

Excellent visualisation

The robotic system provides magnified three-dimensional vision and excellent access to the bladder and prostate.

Precise control of bleeding

Robotic suturing allows individual bleeding vessels to be identified and controlled.

Lower morbidity than traditional open simple prostatectomy

Compared with open surgery, robotic simple prostatectomy generally produces less blood loss, lower transfusion rates and shorter hospitalisation, although robotic operations can take longer.

Simultaneous bladder surgery

Large bladder stones, selected bladder diverticula and other pathology can potentially be managed during the same operation.

Durable removal of obstruction

Because most of the obstructing adenoma is removed, substantial recurrent obstruction from regrowth is uncommon.

Possible complications

As with any major surgical procedure, complications can occur.

Bleeding

Some bleeding is expected because the prostate has a rich blood supply.

Blood transfusion is uncommon with modern robotic techniques but remains possible, particularly with exceptionally large glands, anticoagulant therapy or significant postoperative bleeding.

Rarely, significant bleeding may require return to theatre.

Urinary infection

A urinary infection can occur following surgery or while the catheter is present.

Symptoms can include fever, burning, cloudy urine or feeling systemically unwell.

Blood clots and catheter blockage

Bleeding can produce clots within the bladder.

Continuous bladder irrigation may therefore be used during the early postoperative period. Occasionally a catheter may require irrigation or replacement, and rarely clot evacuation under anaesthesia is necessary.

Temporary urinary incontinence

Some men experience temporary urinary leakage following catheter removal.

This generally improves as the external urinary sphincter adapts to the newly unobstructed urinary channel.

Pelvic floor exercises may assist recovery.

Persistent severe stress urinary incontinence is uncommon but remains a recognised complication.

Urinary urgency

Urgency, frequency and urge incontinence may temporarily become more noticeable after surgery.

Men who had longstanding bladder obstruction may have developed detrusor overactivity or impaired bladder function. Consequently, bladder symptoms may take weeks or months to settle and occasionally require additional treatment.

Bladder neck contracture

Scar tissue can occasionally develop around the bladder outlet.

If significant, this may require an endoscopic procedure to reopen the channel.

Urethral stricture

Scar tissue can develop within the urethra following instrumentation or catheterisation.

This is uncommon but may require dilatation, urethrotomy or, rarely, reconstructive surgery.

Injury to surrounding structures

Rare complications include injury to the:

  • Bladder
  • Ureteric openings
  • Ureter
  • Rectum
  • Bowel
  • Blood vessels

Major complications requiring additional surgery are uncommon but possible.

General surgical complications

These include:

  • Deep vein thrombosis
  • Pulmonary embolism
  • Chest infection
  • Cardiovascular complications
  • Anaesthetic complications
  • Port-site hernia
  • Wound infection

Appropriate preventative measures are used according to individual patient risk.

What happens to ejaculation?

This deserves particular emphasis.

Retrograde or absent ejaculation is very common.

During normal ejaculation, the bladder neck closes and semen travels forward through the urethra.

After removal of a large prostate adenoma, this mechanism is altered. Semen may pass backwards into the bladder or there may be very little visible ejaculate.

The sensation of orgasm usually remains, but ejaculation is frequently dry or markedly reduced.

This can significantly affect fertility and should be discussed before surgery in men who may wish to father children.

What about erections?

Robotic simple prostatectomy is different from radical prostatectomy for prostate cancer.

The prostate capsule and surrounding neurovascular structures are generally preserved.

Consequently, erectile dysfunction is not an inevitable consequence of robotic simple prostatectomy.

Temporary deterioration can occur following any major pelvic operation, particularly in older men with pre-existing vascular or erectile problems, but many men maintain their preoperative erectile function.

Will the prostate grow back?

One of the major advantages of anatomical enucleation is its durability.

The majority of the obstructing adenoma is physically removed rather than simply compressed or partially vaporised.

Some benign prostate tissue remains and can slowly enlarge over many years, so recurrent obstruction is possible, but clinically significant regrowth requiring repeat surgery appears uncommon.

Long-term RASP-specific retreatment data are less mature than data for older procedures because robotic simple prostatectomy is a newer technique. Studies nevertheless show durable functional improvement, and contemporary comparisons demonstrate similar symptom and flow improvements between RASP and anatomical endoscopic enucleation.

For perspective, long-term data for traditional open simple prostatectomy, which uses the same fundamental principle of adenoma enucleation, show endourological reintervention rates of approximately 3% at one year, 6% at five years and 8.8% at eight years. These figures should not be presented as RASP-specific recurrence rates, but they demonstrate the durability of complete adenoma enucleation.

Robotic enucleation versus HoLEP

Both procedures are excellent options for large prostates.

HoLEP removes the adenoma through the urethra using a holmium laser and subsequently morcellates the tissue within the bladder.

Robotic simple prostatectomy approaches the prostate through the abdomen and bladder or prostate capsule.

Recent evidence suggests that both produce substantial and broadly comparable improvements in urinary symptoms, urinary flow and bladder emptying.

HoLEP generally has the advantages of:

  • No abdominal incisions
  • Shorter catheterisation
  • Shorter hospitalisation in many series
  • Very low blood loss
  • Excellent durability

Robotic surgery may be particularly attractive when:

  • The prostate is exceptionally large
  • There are very large bladder stones
  • Concomitant bladder reconstruction is required
  • Prostate anatomy makes a robotic approach advantageous
  • The surgeon has extensive robotic experience
  • Endoscopic enucleation expertise is not available

The best procedure is therefore not determined by prostate volume alone.

Robotic enucleation versus TURP

TURP remains an excellent operation for appropriately sized prostates, but attempting to resect an enormous prostate piece by piece can become a lengthy undertaking.

Robotic enucleation removes the adenoma anatomically and is therefore particularly suited to large-volume disease.

For very large prostates, current guidelines support simple prostatectomy and anatomical endoscopic enucleation rather than assuming conventional TURP is the optimal treatment.

Recovery after robotic prostate enucleation

Hospital stay varies according to the technique, prostate size and individual recovery.

After discharge, patients are generally encouraged to walk regularly but avoid strenuous exercise and heavy lifting during the early healing period.

Blood in the urine may come and go for several weeks, particularly after physical activity.

Patients should seek medical attention for:

  • Inability to pass urine
  • A catheter that stops draining
  • Heavy persistent bleeding
  • Large blood clots
  • Fever or chills
  • Increasing abdominal pain
  • Chest pain or shortness of breath
  • Significant calf swelling or pain

Is robotic-assisted enucleation right for every large prostate?

No.

The decision should take into consideration:

  • Prostate volume and anatomy
  • Severity of urinary symptoms
  • Urinary flow and residual urine
  • Bladder function
  • Previous urinary retention
  • Presence of bladder stones or diverticula
  • PSA and prostate cancer risk
  • Previous prostate surgery
  • Anticoagulant or antiplatelet medication
  • General health
  • Anaesthetic risk
  • Patient priorities regarding ejaculation and sexual function
  • Availability and experience of the treating surgeon

Alternatives may include HoLEP, other forms of endoscopic enucleation, bipolar TURP, GreenLight laser surgery, Aquablation, prostate artery embolisation, medical therapy or continued observation, depending upon prostate size, anatomy and the individual patient’s circumstances.

The bottom line

For men with a very large benign prostate causing significant urinary obstruction, robotic-assisted prostate enucleation offers a powerful and durable surgical solution.

Rather than trimming away small amounts of tissue, the surgeon follows the natural anatomical plane around the prostate adenoma and removes the obstructing tissue almost in its entirety.

The trade-off is that this remains a significant operation, usually requiring several days of catheterisation and a period of recovery. Retrograde or absent ejaculation should be expected, and complications including bleeding, infection, temporary incontinence, bladder neck contracture and urethral stricture can occur.

For the appropriately selected patient, however, the combination of substantial adenoma removal, excellent urinary flow improvement, low retreatment requirements and the precision of robotic surgery makes robotic-assisted simple prostatectomy an important contemporary option for the very large benign prostate.

This information is intended for general patient education and does not replace individual assessment and advice from a urologist.

TURP for Benign Prostatic Hyperplasia (BPH)

/0 Comments/in , /by

The Traditional Benchmark for Prostate Surgery

For decades, Transurethral Resection of the Prostate (TURP) has been one of the most established surgical treatments for urinary obstruction caused by benign prostatic hyperplasia (BPH).

Although newer technologies such as GreenLight laser vaporisation, HoLEP, Aquablation, Rezūm and robotic-assisted simple prostatectomy/enucleation have expanded the treatment menu, TURP remains an important benchmark against which many newer procedures are compared.

The basic principle is refreshingly straightforward: remove the obstructing prostate tissue from the inside and create a wider channel for urine to pass through.

What is BPH?

Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate that commonly occurs as men age.

As the prostate enlarges around the urethra, it may progressively restrict urinary flow. Symptoms can include:

  • A weak urinary stream
  • Difficulty starting urination
  • Straining to urinate
  • Intermittent or stop-start flow
  • Feeling that the bladder has not emptied completely
  • Urinary frequency
  • Urgency
  • Getting up several times at night to urinate
  • Acute or chronic urinary retention

Importantly, prostate size and symptoms do not always travel together. A relatively modest prostate can produce significant obstruction, while some very large prostates cause surprisingly little trouble.

What is a TURP?

TURP stands for Transurethral Resection of the Prostate.

There is no external incision.

A specialised telescope called a resectoscope is passed through the urethra and into the prostate. A small electrical loop is then used to progressively remove pieces of obstructing prostate tissue.

Think less “removing the prostate” and more opening up the tunnel through it.

The outer portion of the prostate remains behind. TURP is therefore very different from a radical prostatectomy, where the entire prostate is removed to treat prostate cancer.

The removed prostate tissue is usually sent to pathology for examination.

Monopolar versus Bipolar TURP

There are two principal forms of TURP.

Monopolar TURP

Traditional monopolar TURP uses electrical current passing between the resection loop and a grounding pad on the patient.

It requires non-conductive irrigation fluid during surgery.

One uncommon but potentially serious complication is TUR syndrome, where excessive absorption of irrigation fluid can cause dilution of the blood sodium concentration.

Bipolar TURP

Modern bipolar TURP allows the electrical circuit to remain localised around the resection electrode and permits the use of normal saline irrigation.

This substantially reduces the risk of TUR syndrome and has made TURP safer, particularly when longer operating times are required.

For this reason, bipolar TURP has become widely used in contemporary practice.

Who Should Consider TURP?

TURP is generally considered when urinary symptoms from benign prostate enlargement are sufficiently troublesome or when BPH begins causing complications.

Common indications include:

Moderate to severe lower urinary tract symptoms

Men whose symptoms remain troublesome despite medication, or who prefer definitive surgical treatment, may benefit from TURP.

Recurrent urinary retention

Repeated episodes requiring catheterisation suggest significant bladder outlet obstruction.

Catheter-dependent urinary retention

Some men become unable to urinate without a catheter. TURP may restore spontaneous voiding, although success also depends on how well the bladder muscle continues to function.

Recurrent urinary tract infections

Incomplete bladder emptying can contribute to recurrent infections.

Bladder stones

Persistent obstruction and residual urine may encourage bladder stone formation.

Recurrent bleeding from an enlarged prostate

Significant or recurrent haematuria attributable to BPH can occasionally be an indication for surgery.

Progressive bladder dysfunction

Longstanding obstruction may cause bladder wall thickening, diverticula, increasing residual urine and eventually impaired bladder contractility.

Kidney impairment or hydronephrosis due to bladder outlet obstruction

This represents an important indication for relieving the obstruction.

What Size Prostate is Suitable for TURP?

TURP has traditionally been particularly suitable for prostates in approximately the 30–80 mL range.

The 2026 European Association of Urology guideline continues to regard TURP as a standard surgical treatment for appropriately selected men with moderate-to-severe lower urinary tract symptoms and prostates in this general size range.

Larger prostates can certainly be treated by TURP, particularly in experienced hands, but increasing gland size means:

  • Longer operating time
  • Greater bleeding risk
  • More tissue requiring resection
  • Potentially incomplete adenoma removal
  • Greater likelihood of requiring staged surgery

For substantially larger glands, anatomical enucleation procedures such as HoLEP or, in selected patients, robotic-assisted simple prostatectomy/enucleation may offer advantages because they remove a greater proportion of the obstructing adenoma.

When Might TURP Not Be Appropriate?

There are relatively few absolute contraindications to TURP, but there are circumstances where surgery should be delayed or another approach considered.

Active urinary infection

A symptomatic urinary tract infection should generally be treated before elective surgery because instrumentation can increase the risk of sepsis.

Uncorrected bleeding disorder

Significant coagulopathy requires appropriate assessment and management before surgery.

Anticoagulant and antiplatelet medications require individualised management. They should never simply be stopped without medical advice, as the risk of bleeding must be balanced against the patient’s cardiovascular or thromboembolic risk.

Severe urethral stricture disease

If a resectoscope cannot safely pass through the urethra, the urethral problem may require treatment first or an alternative surgical strategy may be required.

Very large prostate

This is not an absolute contraindication, but procedures such as HoLEP or robotic/open simple prostatectomy may be more appropriate for some very large glands.

Poor bladder contractility

Not every weak stream is caused purely by the prostate.

A bladder that has become significantly underactive may still empty poorly even after an excellent TURP.

This distinction can be particularly important in men with chronic urinary retention, neurological disease, diabetes or very large residual urine volumes. Urodynamic pressure-flow studies can occasionally help determine whether obstruction, impaired bladder contraction, or a mixture of both is responsible.

What Happens During TURP?

TURP is usually performed under either general or spinal anaesthesia.

The resectoscope is passed through the urethra to the prostate.

The surgeon progressively removes obstructing prostate tissue until a wide channel has been created between the bladder and the urethra.

Bleeding points are cauterised during the procedure.

At completion, a urinary catheter is usually inserted. Continuous bladder irrigation may be used initially to prevent blood clots accumulating inside the bladder.

Most patients remain in hospital until the urine has cleared sufficiently and the catheter can safely be removed.

What Should I Expect Afterwards?

It is common to experience:

  • Blood in the urine
  • Burning or stinging during urination
  • Increased urinary frequency
  • Urgency
  • Temporary difficulty controlling urgency
  • Intermittent blood or small clots for several weeks

The urinary stream often improves relatively quickly, while frequency and urgency can take longer to settle.

This is particularly true when the bladder has been fighting obstruction for many years. Removing the obstruction does not necessarily make an irritable bladder forget its old habits overnight.

Risks and Complications of TURP

TURP is well established and generally safe, but it remains an operation and complications can occur.

Bleeding

Some bleeding is expected.

Occasionally bleeding may be sufficient to require:

  • Prolonged bladder irrigation
  • Blood transfusion
  • Return to theatre for evacuation of blood clots and control of bleeding

Significant transfusion is much less common with contemporary techniques than historically.

Infection

Urinary tract infection can occur following TURP.

Patients with long-term catheters, recurrent infections or significant residual urine may have a higher risk.

Rarely, infection can progress to urosepsis.

Temporary Urinary Retention

Some patients cannot urinate immediately after catheter removal.

The catheter may need to be reinserted temporarily.

This is more likely when the bladder muscle has become weak following longstanding obstruction.

Retrograde Ejaculation

One of the most important long-term consequences of TURP is retrograde ejaculation.

Normally, the bladder neck closes during ejaculation so semen travels forwards through the penis.

After TURP, the bladder neck may remain open during ejaculation. Semen therefore travels backwards into the bladder and is subsequently passed harmlessly with the urine.

The orgasmic sensation is usually preserved, but little or no semen may emerge from the penis.

Retrograde ejaculation is common after conventional TURP and should be discussed before surgery, particularly in younger men concerned about fertility or preservation of ejaculation.

Erectile Dysfunction

Most men do not develop erectile dysfunction simply because they have undergone TURP.

Some men report changes in erectile function after surgery, while others notice improvement associated with better sleep, fewer urinary symptoms and improved general wellbeing.

Age, cardiovascular disease, diabetes, medications and pre-existing erectile dysfunction frequently have a greater influence on erections than the TURP itself.

Urinary Incontinence

Temporary urgency and urge leakage can occur during recovery.

Persistent significant urinary incontinence following uncomplicated TURP is considerably less common.

A contemporary systematic review and meta-analysis of randomised TURP studies reported an overall incontinence rate of approximately 8%, although this includes differing definitions and follow-up intervals and therefore should not be interpreted as an 8% rate of permanent severe incontinence.

Urethral Stricture After TURP

One of the important delayed complications is a urethral stricture.

A stricture is scar tissue that progressively narrows the urethra.

Symptoms may include:

  • A gradually weakening urinary stream
  • Spraying or splitting of the stream
  • Straining
  • Incomplete bladder emptying
  • Recurrent urinary infections
  • Urinary retention

The reported rate varies considerably between studies.

The EAU urethral stricture guideline reports urethral stricture rates following monopolar or bipolar TURP of approximately 1.7–11.7%, reflecting differences in surgical technique, instrumentation, follow-up and definitions.

A more recent systematic review of randomised TURP studies found an overall urethral stricture rate of approximately 3%.

For patient counselling, therefore, a reasonable practical message is:

Urethral stricture occurs in roughly 2–5% of contemporary TURP patients in many series, although reported rates vary more widely.

Potential contributing factors include the diameter of the resectoscope, duration of surgery, urethral trauma, postoperative catheterisation and other technical factors.

A stricture may be treated with urethral dilatation, endoscopic urethrotomy or, for more complex or recurrent strictures, urethroplasty.

Bladder Neck Contracture

Scar tissue can also develop at the bladder neck following TURP.

This is called bladder neck stenosis or bladder neck contracture.

The EAU guideline reports rates following TURP ranging approximately 2.4–9.7%, although contemporary rates vary considerably according to technique and patient population.

It can produce symptoms very similar to recurrent BPH and may require an endoscopic bladder neck incision or resection.

Can the Prostate Grow Back After TURP?

Yes, but perhaps “grow back” is slightly misleading.

TURP removes the obstructing inner portion of the prostate but does not remove the entire prostate gland.

Remaining benign prostate tissue can therefore enlarge over subsequent years.

Some men eventually develop recurrent obstruction and require another operation.

Importantly, not every patient who develops recurrent urinary symptoms has recurrent BPH. Other causes include:

  • Urethral stricture
  • Bladder neck contracture
  • Overactive bladder
  • Underactive bladder
  • Recurrent adenoma
  • Prostate cancer

Assessment is therefore preferable to simply assuming that “the prostate has grown back.”

What is the Redo Rate After TURP?

TURP provides durable symptom improvement for most men, but reoperation becomes more common with increasing follow-up.

A large systematic review involving 119 studies and more than 130,000 patients estimated TURP reoperation rates of approximately:

Time after TURP Reoperation rate
1 year 4.0%
2 years 5.0%
3 years 6.0%
5 years 7.7%

Longer-term population data also demonstrate the durability of TURP. An Austrian nationwide analysis cited by the EAU found actual repeat TURP rates of approximately 2.4% at one year, 6.1% at five years and 8.3% at eight years. When procedures for urethral stricture and bladder neck stenosis were also included, the overall retreatment rate reached approximately 12.7% at eight years.

These figures highlight an important distinction:

“Redo TURP” and “reoperation after TURP” are not necessarily the same thing.

A subsequent procedure might be required because of recurrent prostate obstruction, but it may instead be required to treat a urethral stricture or bladder neck contracture.

TUR Syndrome

Traditional monopolar TURP carries a small risk of TUR syndrome, caused by absorption of large volumes of non-saline irrigation fluid. This is a serious complication occasionally requiring an ICU admission as it can cause brain swelling.

This can result in:

  • Low blood sodium
  • Nausea and vomiting
  • Confusion
  • Blood pressure changes
  • Neurological disturbances
  • Cardiovascular complications

Modern bipolar TURP using saline irrigation has dramatically reduced this particular complication.

Does TURP Cause Prostate Cancer?

No.

BPH and prostate cancer are different diseases.

However, because TURP only removes part of the prostate, prostate cancer can still develop in the remaining gland.

Appropriate PSA surveillance and prostate assessment may therefore still be required after TURP.

Occasionally, unsuspected prostate cancer is discovered when TURP tissue is examined by the pathologist.

Advantages of TURP

TURP remains popular because it offers several important advantages:

  • Long-established procedure
  • Excellent improvement in urinary flow
  • Significant improvement in urinary symptoms
  • No external incision
  • Widely available
  • Tissue is obtained for pathological examination
  • Durable results
  • Particularly effective for appropriately selected medium-sized prostates
  • Extensive long-term outcome data

Despite the arrival of numerous newer technologies, TURP remains an important reference standard for surgical treatment of BPH. Long-term studies demonstrate sustained improvement in urinary symptoms and flow.

Disadvantages of TURP

Potential disadvantages include:

  • Anaesthetic and surgical risks
  • Bleeding
  • Catheterisation and hospital admission
  • Retrograde ejaculation
  • Temporary urinary urgency
  • Infection
  • Urethral stricture
  • Bladder neck contracture
  • Small risk of persistent incontinence
  • Possibility of future retreatment
  • Less suitable than anatomical enucleation for some very large prostates

TURP versus Modern BPH Surgery

TURP remains highly effective, but it is no longer the only surgical option.

Depending on prostate size, anatomy, medications, general health and the importance of preserving ejaculation, alternatives may include:

  • GreenLight laser vaporisation
  • HoLEP
  • Aquablation
  • Rezūm water-vapour therapy
  • Prostatic urethral lift
  • Other minimally invasive surgical therapies
  • Robotic-assisted simple prostatectomy or adenoma enucleation

Long-term comparisons increasingly suggest that anatomical endoscopic enucleation procedures can achieve lower retreatment rates than TURP in appropriately selected patients, particularly with larger glands.

There is therefore no single “best prostate operation” for every patient.

The aim is to match the procedure to the prostate, bladder and priorities of the man attached to them.

The Bottom Line

TURP remains one of the most proven and effective operations for benign prostate obstruction.

It can provide substantial and durable improvement in urinary flow and lower urinary tract symptoms, particularly in men with appropriately sized prostates and confirmed bladder outlet obstruction.

Patients should nevertheless understand the potential longer-term complications. Urethral stricture is generally reported in the low single-digit percentages in contemporary studies, although published rates range more widely. Repeat intervention becomes progressively more likely with longer follow-up, with pooled data suggesting a reoperation rate of approximately 7–8% by five years.

TURP may be the old workhorse of BPH surgery, but it has not wandered off to the retirement paddock just yet. For the right prostate and the right patient, it remains a highly effective treatment.

Important Information

This information is intended for general patient education and does not replace individual medical advice. The most appropriate treatment for BPH depends on prostate size and anatomy, severity of obstruction, bladder function, medications, general health, sexual priorities and personal preferences. A consultation with a urologist can help determine whether TURP or an alternative treatment is most appropriate.

So, if you are having issues with your flow and you want to find out more about your options, come see your local Brisbane and Caboolture urologist, Uro-Jo for advice.

Laser Vaporisation for Benign Prostate Enlargement

/0 Comments/in , /by

A Modern, Low-Bleeding Treatment for an Enlarged Prostate

Benign prostate enlargement, also called benign prostatic hyperplasia (BPH), is extremely common as men get older. As the prostate enlarges around the urethra, it can gradually restrict urinary flow, rather like slowly tightening a collar around the urinary pipe.

Symptoms may include:

  • A slow or weak urinary stream
  • Difficulty starting urination
  • Straining to urinate
  • Intermittent or stop-start flow
  • A feeling that the bladder has not emptied properly
  • Urinary frequency and urgency
  • Getting up several times at night to urinate
  • Episodes of urinary retention

Many men can initially be managed with lifestyle modification or medication. When symptoms become troublesome, complications develop, or medication is no longer effective or desirable, surgery may be considered.

One well-established minimally invasive surgical option is GreenLight laser photoselective vaporisation of the prostate (PVP).

What Is GreenLight Laser Prostate Surgery?

GreenLight PVP is an endoscopic procedure performed through the urethra. There are no abdominal incisions.

A telescope is passed through the urethra to the prostate. A specialised laser fibre is then used to progressively vaporise the obstructing prostate tissue and create a wider channel through which urine can flow.

Unlike TURP, where pieces of prostate tissue are physically cut away, GreenLight treatment predominantly converts the obstructing tissue into vapour while simultaneously sealing blood vessels.

The result is a combination of tissue removal and excellent haemostasis.

What Laser Is Used?

The GreenLight system uses a 532-nanometre green laser.

Modern GreenLight systems commonly use a lithium triborate (LBO) crystal to generate the 532 nm wavelength, with the contemporary high-powered platform delivering up to 180 watts.

Earlier systems included:

Generation Laser Maximum power
Early GreenLight KTP 80 W
GreenLight HPS LBO 120 W
GreenLight XPS LBO 180 W

The current European Association of Urology guideline describes the 180 W system as the contemporary standard platform for GreenLight PVP.

Why Is the Laser Green?

The colour is not merely decorative.

The 532 nm wavelength is strongly absorbed by haemoglobin, the pigment contained within red blood cells. It is much less strongly absorbed by water.

This property allows the laser energy to be preferentially absorbed by the vascular prostate tissue.

The laser has a relatively shallow tissue penetration of approximately 0.8 mm, producing rapid vaporisation while creating a limited zone of coagulation underneath the treated surface.

This gives GreenLight its two particularly useful characteristics:

Vaporisation + haemostasis

As prostate tissue is vaporised, small blood vessels are simultaneously coagulated.

This is why the operative field can remain remarkably clear and why GreenLight surgery generally produces less bleeding than traditional TURP.

Who May Benefit from GreenLight Laser Surgery?

GreenLight PVP may be considered for men with moderate to severe urinary symptoms caused by benign prostatic obstruction, particularly when conservative or medical treatment has not provided adequate relief.

Surgery may also be recommended when BPH results in complications such as:

  • Recurrent urinary retention
  • Dependence on a urinary catheter
  • Recurrent urinary tract infections associated with obstruction
  • Bladder stones
  • Recurrent visible haematuria attributable to BPH
  • Progressive bladder dysfunction
  • Significant residual urine
  • Upper urinary tract deterioration or renal impairment secondary to obstruction

Surgery is also reasonable when symptoms remain sufficiently troublesome despite medication, or when a patient does not wish to continue long-term medical therapy.

What Size Prostate Can Be Treated?

GreenLight PVP is particularly well established for prostates approximately 30–80 mL in volume.

The 2026 European Association of Urology guidelines recommend 532 nm GreenLight PVP as an alternative to TURP for men with moderate-to-severe LUTS and benign prostatic obstruction in this prostate-size range.

Larger prostates can certainly be treated by experienced GreenLight surgeons, but the operation becomes progressively more time-consuming as prostate volume increases.

Importantly, evidence supporting PVP in prostates above approximately 100 mL is less robust than the evidence supporting anatomical enucleation procedures such as HoLEP.

The AUA guideline similarly notes that PVP may be less effective in very large prostates and that retreatment becomes an increasingly important consideration.

For a very large prostate, HoLEP or robotic-assisted simple prostatectomy/enucleation may therefore provide more complete adenoma removal.

What Happens During GreenLight PVP?

The operation is usually performed under general or spinal anaesthesia.

A telescope is passed through the penis and urethra until the obstructing prostate is visualised.

The laser fibre is introduced through the telescope.

The surgeon progressively vaporises the obstructing prostate tissue, generally working from the bladder neck towards the apex of the prostate while carefully protecting the urinary sphincter.

The goal is not necessarily to remove the entire prostate.

Instead, the obstructing transition-zone tissue is removed sufficiently to create a wide, low-resistance urinary channel.

A urinary catheter is usually placed at the end of the operation.

Because bleeding is generally limited, catheterisation and hospitalisation can often be shorter than following conventional TURP.

Some appropriately selected patients can undergo the procedure as day surgery.

Advantages of GreenLight Laser Surgery

Less bleeding

This is arguably GreenLight’s greatest strength.

Because the 532 nm wavelength is absorbed by haemoglobin, tissue vaporisation and coagulation occur simultaneously.

Compared with TURP, studies have demonstrated lower transfusion rates and less bleeding.

Particularly useful when bleeding risk matters

GreenLight may be attractive in older patients or men with cardiovascular disease who require antiplatelet or anticoagulant medication.

The EAU guidelines specifically recognise GreenLight PVP as an option in selected patients receiving anticoagulant or antiplatelet therapy, although individual management of these medications still needs to be determined before surgery.

Shorter catheterisation

Many patients can have their catheter removed relatively quickly after surgery.

Shorter hospital stay

GreenLight surgery is frequently suitable for overnight or even day-case treatment in appropriately selected patients.

No external incision

The entire procedure is performed through the urethra.

No TUR syndrome

GreenLight PVP uses saline irrigation and does not carry the classical dilutional hyponatraemia or “TUR syndrome” associated with older monopolar TURP techniques.

Effective symptom improvement

GreenLight PVP can produce substantial improvements in:

  • Urinary flow
  • Bladder emptying
  • IPSS symptom scores
  • Quality of life

Randomised trials of contemporary GreenLight PVP have demonstrated symptom and flow improvements broadly comparable with TURP over short- to medium-term follow-up.

What Are the Side Effects?

Most men experience some temporary urinary irritation during the recovery period.

Burning or stinging when urinating

This is common initially and usually improves as the prostatic urethra heals.

Urinary frequency and urgency

The bladder may remain irritable for several weeks.

It is important to remember that removing the obstruction does not instantly reset a bladder that may have been struggling against that obstruction for many years.

Blood in the urine

Small amounts of bleeding can occur intermittently during healing, despite the excellent haemostatic properties of the laser.

Temporary difficulty urinating

Occasionally swelling after surgery means that the catheter needs to remain in place longer or needs to be reinserted.

Urinary infection

As with any endoscopic urinary procedure, urinary infection can occur.

Retrograde Ejaculation

One of the most important issues to discuss before surgery is ejaculation.

Following conventional GreenLight PVP, semen may travel backwards into the bladder rather than forwards through the penis during orgasm.

This is called retrograde ejaculation.

The orgasm usually remains present, but little or no semen may be produced.

This is particularly important for younger men concerned about fertility or preservation of ejaculation.

GreenLight should therefore not automatically be described as an “ejaculation-preserving” operation.

Does GreenLight Cause Erectile Dysfunction?

For most men, erectile function is preserved.

Current evidence does not demonstrate a major difference in erectile-function outcomes between GreenLight PVP and conventional TURP.

Sexual function, however, is influenced by many factors including age, vascular health, diabetes, medications and pre-existing erectile function.

Less Common Complications

Potential complications include:

  • Significant bleeding
  • Urinary tract infection
  • Temporary urinary retention
  • Urethral stricture
  • Bladder-neck contracture
  • Temporary urinary incontinence
  • Rare persistent urinary incontinence
  • Persistent urgency or overactive bladder symptoms
  • Incomplete removal of obstructing tissue
  • Recurrent prostate enlargement
  • Requirement for further prostate surgery

One Important Limitation: There Is Usually No Tissue for Pathology

This is an important difference between GreenLight PVP and TURP or HoLEP.

With TURP, prostate chips are removed.

With HoLEP, the enucleated adenoma is morcellated and retrieved.

With GreenLight PVP, much of the treated tissue is vaporised.

Consequently, there may be little or no prostate tissue available for histological examination.

For this reason, appropriate assessment for prostate cancer should be undertaken before GreenLight surgery when clinically indicated, using PSA, examination, MRI and/or prostate biopsy where appropriate.

GreenLight vs TURP vs HoLEP vs Robotic-Assisted Simple Prostatectomy

There is no single “best” prostate operation for every man.

The appropriate procedure depends on:

prostate size + prostate anatomy + bleeding risk + bladder function + patient priorities + surgeon expertise.

Feature GreenLight PVP TURP HoLEP Robotic Simple Prostatectomy / Enucleation
Approach Transurethral Transurethral Transurethral Abdominal robotic
Energy 532 nm laser Electrical 2,140 nm holmium laser Robotic dissection ± energy
Tissue treatment Vaporisation Resection Anatomical enucleation Anatomical enucleation
Tissue for pathology Limited/none Yes Yes Yes
Bleeding Very low Low-moderate Very low Low-moderate
Best established size ~30–80 mL ~30–80 mL Virtually size-independent Large/very large prostates
Large prostate >100 mL Possible, but less ideal Less attractive Excellent option Excellent option
Catheter duration Usually short Short Usually short Usually longer
Hospital stay Short Short Short Generally longer
Anticoagulation advantage Good Less favourable Good Less favourable
Learning curve Moderate Familiar technique Significant Significant
Durability in very large glands Less certain Good Excellent Excellent
Incisions None None None Abdominal port incisions

GreenLight vs TURP

TURP has traditionally been regarded as the benchmark operation against which newer BPH procedures are compared.

GreenLight achieves broadly similar improvements in urinary symptoms and flow for appropriately selected prostates.

Its principal advantages over TURP are:

  • Less perioperative bleeding
  • Lower transfusion requirements
  • Shorter catheterisation
  • Shorter hospitalisation
  • Excellent visibility during surgery
  • Potential advantages in patients at increased bleeding risk

Its disadvantages include:

  • Longer operating time in some patients
  • Lack of tissue for histology
  • Potentially higher retreatment rates over longer follow-up
  • Reduced efficiency as prostate size becomes very large

Long-term population data suggest that although reoperations for bleeding are less common after PVP, overall cumulative reoperation may be higher than after TURP.

So GreenLight’s strength is low perioperative morbidity, while TURP retains excellent durability and provides tissue for histology.

GreenLight vs HoLEP

HoLEP is fundamentally different.

GreenLight predominantly vaporises the obstructing prostate.

HoLEP enucleates the adenoma anatomically from the surgical capsule, rather like removing the inside of an orange while leaving the peel behind.

HoLEP uses a pulsed 2,140 nm holmium laser, which is strongly absorbed by water rather than haemoglobin.

The major advantage of HoLEP is that it is essentially prostate-size independent.

A 40 mL prostate can be enucleated.

So can a 100, 150 or even 200+ mL prostate in experienced hands.

The AUA guideline specifically recognises HoLEP as a prostate size-independent surgical option.

HoLEP also removes a larger proportion of the obstructing adenoma and provides tissue for histological examination.

Its principal disadvantages are its technical complexity, significant learning curve and potential for temporary postoperative stress urinary incontinence, particularly following treatment of very large glands.

For very large prostates, HoLEP will generally provide more complete anatomical adenoma removal than conventional GreenLight vaporisation.

GreenLight vs Robotic-Assisted Prostate Enucleation

For very large benign prostates, another option is robot-assisted simple prostatectomy (RASP), sometimes described as robotic prostate adenoma enucleation.

This is very different from a robotic radical prostatectomy performed for prostate cancer.

The entire prostate is not removed.

Instead, the enlarged benign adenoma is dissected away from the remaining prostate capsule.

It essentially achieves the same anatomical objective as HoLEP but approaches the prostate through the abdomen and bladder or prostate capsule rather than through the urethra.

Robotic simple prostatectomy is particularly attractive for very large or anatomically complex prostates, particularly when associated bladder pathology can be addressed simultaneously.

Its disadvantages include:

  • Abdominal surgery
  • Robotic port incisions
  • Longer catheterisation
  • Longer hospital stay
  • Greater surgical invasiveness
  • Higher resource utilisation

Recent comparative evidence suggests that both robotic simple prostatectomy and laser enucleation provide excellent outcomes for prostates ≥80 mL, while endoscopic laser enucleation generally provides faster perioperative recovery.

So Which Operation Is Best?

A useful way of thinking about these procedures is not as competitors, but as different tools for different prostates.

GreenLight PVP

Particularly attractive for:

  • Small-to-moderately enlarged prostates
  • Approximately 30–80 mL glands
  • Patients where minimising bleeding is particularly important
  • Older or medically complex patients
  • Patients requiring rapid recovery and short catheterisation

TURP

Remains an excellent option for:

  • Small-to-moderately enlarged prostates
  • Conventional benign prostatic obstruction
  • Situations where prostate tissue for histology is desirable
  • Centres with extensive TURP experience

HoLEP

Particularly attractive for:

  • Moderate, large and extremely large prostates
  • Men requiring maximal adenoma removal
  • Recurrent BPH after previous surgery
  • Patients where long-term durability is particularly important
  • Patients wishing to avoid abdominal surgery despite a very large prostate

Robotic-Assisted Simple Prostatectomy

Particularly attractive for:

  • Very large prostates
  • Complex prostate anatomy
  • Large intravesical adenomas
  • Patients with associated bladder pathology requiring treatment
  • Situations where endoscopic enucleation expertise is unavailable or a robotic approach offers anatomical advantages

The Bottom Line

GreenLight laser photoselective vaporisation is an effective, minimally invasive surgical treatment for benign prostate enlargement.

Its 532 nm laser is selectively absorbed by haemoglobin, allowing prostate tissue to be vaporised while simultaneously achieving excellent haemostasis.

Its particular strengths are:

less bleeding, short catheterisation, short hospitalisation and rapid recovery.

For appropriately selected men with moderate-sized prostates, symptom improvement is broadly comparable with TURP.

As prostate size increases, however, anatomical enucleation becomes increasingly attractive. HoLEP and robotic-assisted simple prostatectomy remove the adenoma more completely and are particularly effective for very large prostates. HoLEP achieves this endoscopically, whereas robotic surgery achieves it through an abdominal approach.

The choice therefore should not simply be:

“Which operation is newest?”

A better question is:

“Which operation best suits this prostate, this bladder and this patient?”

Prostate size and shape, urinary symptoms, bladder function, bleeding risk, medications, general health, PSA assessment, sexual priorities and the surgeon’s experience should all contribute to the final decision.

This information is intended for general patient education and does not replace individual assessment and discussion with a urologist.